메뉴 건너뛰기




Volumn 170, Issue , 2017, Pages 148-165

The Na+-D-glucose cotransporters SGLT1 and SGLT2 are targets for the treatment of diabetes and cancer

Author keywords

Anticancer therapy; Antidiabetic therapy; Glucose sensor; Na+ D glucose cotransporter; SGLT inhibitors; SLC5 family

Indexed keywords

GLUCOSE; RETINOSCHISIN; SODIUM GLUCOSE COTRANSPORTER 1; SODIUM GLUCOSE COTRANSPORTER 1 INHIBITOR; SODIUM GLUCOSE COTRANSPORTER 2; SODIUM GLUCOSE COTRANSPORTER 2 INHIBITOR; SODIUM GLUCOSE COTRANSPORTER 3; SODIUM GLUCOSE COTRANSPORTER INHIBITOR; UNCLASSIFIED DRUG; URATE; ANTIDIABETIC AGENT; ANTINEOPLASTIC AGENT; GLUCOSE BLOOD LEVEL; SLC5A1 PROTEIN, HUMAN; SLC5A2 PROTEIN, HUMAN;

EID: 85006013723     PISSN: 01637258     EISSN: 1879016X     Source Type: Journal    
DOI: 10.1016/j.pharmthera.2016.10.017     Document Type: Review
Times cited : (122)

References (271)
  • 1
    • 84948403433 scopus 로고    scopus 로고
    • Renal sodium-glucose cotransporter inhibition in the management of type 2 diabetes mellitus
    • Abdul-Ghani, M.A., Norton, L., DeFronzo, R.A., Renal sodium-glucose cotransporter inhibition in the management of type 2 diabetes mellitus. Am J Physiol Renal Physiol 309 (2015), F889–F900.
    • (2015) Am J Physiol Renal Physiol , vol.309 , pp. F889-F900
    • Abdul-Ghani, M.A.1    Norton, L.2    DeFronzo, R.A.3
  • 2
    • 77953759683 scopus 로고    scopus 로고
    • Functional characterization of mouse/glucose transporter type 3b
    • Aljure, O., Dίez-Sampedro, A., Functional characterization of mouse/glucose transporter type 3b. Am J Physiol Cell Physiol 299 (2010), C58–C65.
    • (2010) Am J Physiol Cell Physiol , vol.299 , pp. C58-C65
    • Aljure, O.1    Dίez-Sampedro, A.2
  • 4
    • 80054122252 scopus 로고    scopus 로고
    • NADPH oxidase activation by hyperglycaemia in cardiomyocytes is independent of glucose metabolism but requires SGLT1
    • Balteau, M., Tajeddine, N., de Meesters, C., Ginion, A., Des Rosiers, C., Brady, N.R., Sommereyns, C., et al. NADPH oxidase activation by hyperglycaemia in cardiomyocytes is independent of glucose metabolism but requires SGLT1. Cardiovasc Res 92 (2011), 237–246.
    • (2011) Cardiovasc Res , vol.92 , pp. 237-246
    • Balteau, M.1    Tajeddine, N.2    de Meesters, C.3    Ginion, A.4    Des Rosiers, C.5    Brady, N.R.6    Sommereyns, C.7
  • 5
    • 70449729537 scopus 로고    scopus 로고
    • SGLT1 is a novel cardiac glucose transporter that is perturbed in disease states
    • Banerjee, S.K., McGaffin, K.R., Pastor-Soler, N.M., Ahmad, F., SGLT1 is a novel cardiac glucose transporter that is perturbed in disease states. Cardiovasc Res 84 (2009), 111–118.
    • (2009) Cardiovasc Res , vol.84 , pp. 111-118
    • Banerjee, S.K.1    McGaffin, K.R.2    Pastor-Soler, N.M.3    Ahmad, F.4
  • 6
    • 84859773735 scopus 로고    scopus 로고
    • Mouse SGLT3a generates proton-activated currents but does not transport sugar
    • Barcelona, S., Menegaz, D., Dίez-Sampedro, A., Mouse SGLT3a generates proton-activated currents but does not transport sugar. Am J Cell Physiol 302 (2012), C1073–C1082.
    • (2012) Am J Cell Physiol , vol.302 , pp. C1073-C1082
    • Barcelona, S.1    Menegaz, D.2    Dίez-Sampedro, A.3
  • 8
    • 0023162229 scopus 로고
    • Fluid absorption by rat lung in situ: Pathways for sodium entry in the luminal membrane of alveolar epithelium
    • Basset, G., Crone, C., Saumon, G., Fluid absorption by rat lung in situ: Pathways for sodium entry in the luminal membrane of alveolar epithelium. J Physiol 384 (1987), 325–345.
    • (1987) J Physiol , vol.384 , pp. 325-345
    • Basset, G.1    Crone, C.2    Saumon, G.3
  • 10
    • 77956316182 scopus 로고    scopus 로고
    • A single amino acid change converts the sugar sensor SGLT3 into a sugar transporter
    • Bianchi, L., Dίez-Sampedro, A., A single amino acid change converts the sugar sensor SGLT3 into a sugar transporter. PLoS One, 5, 2010, e10241.
    • (2010) PLoS One , vol.5
    • Bianchi, L.1    Dίez-Sampedro, A.2
  • 11
    • 33645982255 scopus 로고    scopus 로고
    • From mice to men: insights into the insulin resistance syndromes
    • Biddinger, S.B., Kahn, C.R., From mice to men: insights into the insulin resistance syndromes. Annu Rev Physiol 68 (2006), 123–158.
    • (2006) Annu Rev Physiol , vol.68 , pp. 123-158
    • Biddinger, S.B.1    Kahn, C.R.2
  • 12
    • 84928317576 scopus 로고    scopus 로고
    • Combination therapy for patients with uncontrolled type 2 diabetes mellitus: Adding empagliflozin to pioglitazone or pioglitazone plus metformin
    • Blevins, T., Combination therapy for patients with uncontrolled type 2 diabetes mellitus: Adding empagliflozin to pioglitazone or pioglitazone plus metformin. Expert Opin Drug Saf 14 (2015), 789–793.
    • (2015) Expert Opin Drug Saf , vol.14 , pp. 789-793
    • Blevins, T.1
  • 13
    • 84937763347 scopus 로고    scopus 로고
    • Inhibition of the glucose transporter SGLT2 with dapagliflozin in pancreatic alpha cells triggers glucagon secretion
    • Bonner, C., Kerr-Conte, J., Gmyr, V., Queniat, G., Moerman, E., Thevenet, J., et al. Inhibition of the glucose transporter SGLT2 with dapagliflozin in pancreatic alpha cells triggers glucagon secretion. Nat Med 21 (2015), 512–517.
    • (2015) Nat Med , vol.21 , pp. 512-517
    • Bonner, C.1    Kerr-Conte, J.2    Gmyr, V.3    Queniat, G.4    Moerman, E.5    Thevenet, J.6
  • 14
    • 0020587246 scopus 로고
    • Hemodynamically mediated glomerular injury and the progressive nature of kidney disease
    • Brenner, B.M., Hemodynamically mediated glomerular injury and the progressive nature of kidney disease. Kidney Int 23 (1983), 647–655.
    • (1983) Kidney Int , vol.23 , pp. 647-655
    • Brenner, B.M.1
  • 16
    • 20044376702 scopus 로고    scopus 로고
    • The pathobiology of diabetic complications: A unifying mechanism
    • Brownlee, M., The pathobiology of diabetic complications: A unifying mechanism. Diabetes 54 (2005), 1615–1625.
    • (2005) Diabetes , vol.54 , pp. 1615-1625
    • Brownlee, M.1
  • 18
    • 79251517382 scopus 로고    scopus 로고
    • Regulation of cancer cell metabolism
    • Cairns, R.A., Harris, I.S., Mak, T.W., Regulation of cancer cell metabolism. Nat Rev Cancer 11 (2011), 85–95.
    • (2011) Nat Rev Cancer , vol.11 , pp. 85-95
    • Cairns, R.A.1    Harris, I.S.2    Mak, T.W.3
  • 19
    • 84896713507 scopus 로고    scopus 로고
    • Sodium glucose cotransporter 1 ligand BLF501 as a novel tool for management of gastrointestinal mucositis
    • Cardani, D., Sardi, C., La Ferla, B., D'Orazio, G., Sommariva, M., Marcucci, F., et al. Sodium glucose cotransporter 1 ligand BLF501 as a novel tool for management of gastrointestinal mucositis. Mol Cancer, 13, 2014, 23.
    • (2014) Mol Cancer , vol.13 , pp. 23
    • Cardani, D.1    Sardi, C.2    La Ferla, B.3    D'Orazio, G.4    Sommariva, M.5    Marcucci, F.6
  • 21
    • 34248191309 scopus 로고    scopus 로고
    • Thioglycosides as inhibitors of hSGLT1 and hSGLT2: Potential therapeutic agents for the control of hyperglycemia in diabetes
    • Castaneda, F., Burse, A., Boland, W., Kinne, R.K., Thioglycosides as inhibitors of hSGLT1 and hSGLT2: Potential therapeutic agents for the control of hyperglycemia in diabetes. Int J Med Sci 4 (2007), 131–139.
    • (2007) Int J Med Sci , vol.4 , pp. 131-139
    • Castaneda, F.1    Burse, A.2    Boland, W.3    Kinne, R.K.4
  • 22
    • 77951701615 scopus 로고    scopus 로고
    • Protein kinase C mediated intracellular signaling pathways are involved in the regulation of sodium-dependent glucose co-transporter SGLT1 activity
    • Castaneda-Sceppa, C., Subramanian, S., Castaneda, F., Protein kinase C mediated intracellular signaling pathways are involved in the regulation of sodium-dependent glucose co-transporter SGLT1 activity. J Cell Biochem 109 (2010), 1109–1117.
    • (2010) J Cell Biochem , vol.109 , pp. 1109-1117
    • Castaneda-Sceppa, C.1    Subramanian, S.2    Castaneda, F.3
  • 23
    • 84884167643 scopus 로고    scopus 로고
    • Efficacy and safety of canagliflozin versus glimepiride in patients with type 2 diabetes inadequately controlled with metformin (CANTATA-SU): 52 week results from a randomised, double-blind, phase 3 non-inferiority trial
    • Cefalu, W.T., Leiter, L.A., Yoon, K.H., Arias, P., Niskanen, L., Xie, J., et al. Efficacy and safety of canagliflozin versus glimepiride in patients with type 2 diabetes inadequately controlled with metformin (CANTATA-SU): 52 week results from a randomised, double-blind, phase 3 non-inferiority trial. Lancet 382 (2013), 941–950.
    • (2013) Lancet , vol.382 , pp. 941-950
    • Cefalu, W.T.1    Leiter, L.A.2    Yoon, K.H.3    Arias, P.4    Niskanen, L.5    Xie, J.6
  • 24
    • 0031405798 scopus 로고    scopus 로고
    • Upregulation of SGLT-1 transport activity in rat jejunum induced by GLP-2 infusion in vivo
    • Cheeseman, C.I., Upregulation of SGLT-1 transport activity in rat jejunum induced by GLP-2 infusion in vivo. Am J Phys 273 (1997), R1965–R1971.
    • (1997) Am J Phys , vol.273 , pp. R1965-R1971
    • Cheeseman, C.I.1
  • 25
    • 79952721660 scopus 로고    scopus 로고
    • Quantitative PCR tissue expression profiling of the human SGLT2 gene and related family members
    • Chen, J., Williams, S., Ho, S., Loraine, H., Hagan, D., Whaley, J.M., Feder, J.N., Quantitative PCR tissue expression profiling of the human SGLT2 gene and related family members. Diabetes Ther 1 (2010), 57–92.
    • (2010) Diabetes Ther , vol.1 , pp. 57-92
    • Chen, J.1    Williams, S.2    Ho, S.3    Loraine, H.4    Hagan, D.5    Whaley, J.M.6    Feder, J.N.7
  • 26
    • 84960439287 scopus 로고    scopus 로고
    • Comparative effectiveness of sodium-glucose co-transporter 2 inhibitors for controlling hyperglycaemia in patients with type 2 diabetes: Protocol for a systematic review and network meta-analysis
    • Chen, M., Xie, C.G., Gao, H., Zheng, H., Chen, Q., Fang, J.Q., Comparative effectiveness of sodium-glucose co-transporter 2 inhibitors for controlling hyperglycaemia in patients with type 2 diabetes: Protocol for a systematic review and network meta-analysis. BMJ Open, 6, 2016, e010252.
    • (2016) BMJ Open , vol.6
    • Chen, M.1    Xie, C.G.2    Gao, H.3    Zheng, H.4    Chen, Q.5    Fang, J.Q.6
  • 27
    • 84971663895 scopus 로고    scopus 로고
    • The effects of empagliflozin, an SGLT2 inhibitor, on pancreatic beta-cell mass and glucose homeostasis in type 1 diabetes
    • Cheng, S.T., Chen, L., Li, S.Y., Mayoux, E., Leung, P.S., The effects of empagliflozin, an SGLT2 inhibitor, on pancreatic beta-cell mass and glucose homeostasis in type 1 diabetes. PLoS One, 11, 2016, e0147391.
    • (2016) PLoS One , vol.11
    • Cheng, S.T.1    Chen, L.2    Li, S.Y.3    Mayoux, E.4    Leung, P.S.5
  • 28
    • 84892959743 scopus 로고    scopus 로고
    • The effect of empagliflozin on arterial stiffness and heart rate variability in subjects with uncomplicated type 1 diabetes mellitus
    • Cherney, D.Z., Perkins, B.A., Soleymanlou, N., Har, R., Fagan, N., Johansen, O.E., et al. The effect of empagliflozin on arterial stiffness and heart rate variability in subjects with uncomplicated type 1 diabetes mellitus. Cardiovasc Diabetol, 13, 2014, 28.
    • (2014) Cardiovasc Diabetol , vol.13 , pp. 28
    • Cherney, D.Z.1    Perkins, B.A.2    Soleymanlou, N.3    Har, R.4    Fagan, N.5    Johansen, O.E.6
  • 29
    • 84893214045 scopus 로고    scopus 로고
    • Renal hemodynamic effect of sodium-glucose cotransporter 2 inhibition in patients with type 1 diabetes mellitus
    • Cherney, D.Z., Perkins, B.A., Soleymanlou, N., Maione, M., Lai, V., Lee, A., et al. Renal hemodynamic effect of sodium-glucose cotransporter 2 inhibition in patients with type 1 diabetes mellitus. Circulation 129 (2014), 587–597.
    • (2014) Circulation , vol.129 , pp. 587-597
    • Cherney, D.Z.1    Perkins, B.A.2    Soleymanlou, N.3    Maione, M.4    Lai, V.5    Lee, A.6
  • 30
    • 84975153660 scopus 로고    scopus 로고
    • The effect of sodium glucose cotransporter 2 inhibition with empagliflozin on microalbuminuria in patients with type 2 diabetes
    • Cherney, D., Lund, S.S., Perkins, B.A., Groop, P.-H., Cooper, M.E., Kaspers, S., et al. The effect of sodium glucose cotransporter 2 inhibition with empagliflozin on microalbuminuria in patients with type 2 diabetes. Diabetologia, 2016, 10.1007/s00125-016-4008-2.
    • (2016) Diabetologia
    • Cherney, D.1    Lund, S.S.2    Perkins, B.A.3    Groop, P.-H.4    Cooper, M.E.5    Kaspers, S.6
  • 31
    • 85052043849 scopus 로고    scopus 로고
    • Protein RS1 (RSC1A1) downregulates the exocytotic pathway of glucose transporter SGLT1 at low intracellular glucose via inhibition of ornithine decarboxylase
    • Chintalapathi, C., Keller, T., Müller, T.D., Gorboulev, V., Schäfer, N., Zilkowski, I., et al. Protein RS1 (RSC1A1) downregulates the exocytotic pathway of glucose transporter SGLT1 at low intracellular glucose via inhibition of ornithine decarboxylase. Mol Pharmacol 90 (2016), 1–15.
    • (2016) Mol Pharmacol , vol.90 , pp. 1-15
    • Chintalapathi, C.1    Keller, T.2    Müller, T.D.3    Gorboulev, V.4    Schäfer, N.5    Zilkowski, I.6
  • 32
    • 84894148643 scopus 로고    scopus 로고
    • Glucagon-like peptide-1: Glucose homeostasis and beyond
    • Cho, Y.M., Fujita, Y., Kieffer, T.J., Glucagon-like peptide-1: Glucose homeostasis and beyond. Annu Rev Physiol 76 (2014), 535–559.
    • (2014) Annu Rev Physiol , vol.76 , pp. 535-559
    • Cho, Y.M.1    Fujita, Y.2    Kieffer, T.J.3
  • 33
    • 0036446251 scopus 로고    scopus 로고
    • The effect of epidermal growth factor on the distribution of SGLT-1 in rabbit jejunum
    • Chung, B.M., Wallace, L.E., Hardin, J.A., Gall, D.G., The effect of epidermal growth factor on the distribution of SGLT-1 in rabbit jejunum. Can J Physiol Pharmacol 80 (2002), 872–878.
    • (2002) Can J Physiol Pharmacol , vol.80 , pp. 872-878
    • Chung, B.M.1    Wallace, L.E.2    Hardin, J.A.3    Gall, D.G.4
  • 35
    • 0028133185 scopus 로고
    • Effect of arterial-portal glucose gradients and phloridzin on bile glucose levels in perfused rat liver
    • Crafer, S.M., Pryor, J.S., Dawson, A.P., Effect of arterial-portal glucose gradients and phloridzin on bile glucose levels in perfused rat liver. J Physiol 479 (1994), 281–289.
    • (1994) J Physiol , vol.479 , pp. 281-289
    • Crafer, S.M.1    Pryor, J.S.2    Dawson, A.P.3
  • 36
    • 66149088144 scopus 로고    scopus 로고
    • Nonalcoholic fatty liver disease in type 2 diabetes mellitus
    • Cusi, K., Nonalcoholic fatty liver disease in type 2 diabetes mellitus. Curr Opin Endocrinol Diabetes Obes 16 (2009), 141–149.
    • (2009) Curr Opin Endocrinol Diabetes Obes , vol.16 , pp. 141-149
    • Cusi, K.1
  • 37
    • 4143151942 scopus 로고    scopus 로고
    • Pathogenesis of type 2 diabetes mellitus
    • DeFronzo, R.A., Pathogenesis of type 2 diabetes mellitus. Med Clin North Am 88 (2004), 787–835.
    • (2004) Med Clin North Am , vol.88 , pp. 787-835
    • DeFronzo, R.A.1
  • 38
    • 64649104158 scopus 로고    scopus 로고
    • Banting lecture. From the triumvirate to the ominous octet: a new paradigm for the treatment of type 2 diabetes mellitus
    • DeFronzo, R.A., Banting lecture. From the triumvirate to the ominous octet: a new paradigm for the treatment of type 2 diabetes mellitus. Diabetes 58 (2009), 773–795.
    • (2009) Diabetes , vol.58 , pp. 773-795
    • DeFronzo, R.A.1
  • 40
    • 83655193529 scopus 로고    scopus 로고
    • The role of the kidneys in glucose homeostasis: A new path towards normalizing glycaemia
    • DeFronzo, R.A., Davidson, J.A., Del, P.S., The role of the kidneys in glucose homeostasis: A new path towards normalizing glycaemia. Diabetes Obes Metab 14 (2012), 5–14.
    • (2012) Diabetes Obes Metab , vol.14 , pp. 5-14
    • DeFronzo, R.A.1    Davidson, J.A.2    Del, P.S.3
  • 41
    • 84891865819 scopus 로고    scopus 로고
    • Characterization of renal glucose reabsorption in response to dapagliflozin in healthy subjects and subjects with type 2 diabetes
    • DeFronzo, R.A., Hompesch, M., Kasichayanula, S., Liu, X., Hong, Y., Pfister, M., et al. Characterization of renal glucose reabsorption in response to dapagliflozin in healthy subjects and subjects with type 2 diabetes. Diabetes Care 36 (2013), 3169–3176.
    • (2013) Diabetes Care , vol.36 , pp. 3169-3176
    • DeFronzo, R.A.1    Hompesch, M.2    Kasichayanula, S.3    Liu, X.4    Hong, Y.5    Pfister, M.6
  • 42
    • 84928176749 scopus 로고    scopus 로고
    • Combination of empagliflozin and linagliptin as second-line therapy in subjects with type 2 diabetes inadequately controlled on metformin
    • DeFronzo, R.A., Lewin, A., Patel, S., Liu, D., Kaste, R., Woerle, H.J., Broedl, U.C., Combination of empagliflozin and linagliptin as second-line therapy in subjects with type 2 diabetes inadequately controlled on metformin. Diabetes Care 38 (2015), 384–393.
    • (2015) Diabetes Care , vol.38 , pp. 384-393
    • DeFronzo, R.A.1    Lewin, A.2    Patel, S.3    Liu, D.4    Kaste, R.5    Woerle, H.J.6    Broedl, U.C.7
  • 43
    • 84928426587 scopus 로고    scopus 로고
    • Long-term glycaemic response and tolerability of dapagliflozin versus a sulphonylurea as add-on therapy to metformin in patients with type 2 diabetes: 4-Year data
    • Del, P.S., Nauck, M., Duran-Garcia, S., Maffei, L., Rohwedder, K., Theuerkauf, A., Parikh, S., Long-term glycaemic response and tolerability of dapagliflozin versus a sulphonylurea as add-on therapy to metformin in patients with type 2 diabetes: 4-Year data. Diabetes Obes Metab 17 (2015), 581–590.
    • (2015) Diabetes Obes Metab , vol.17 , pp. 581-590
    • Del, P.S.1    Nauck, M.2    Duran-Garcia, S.3    Maffei, L.4    Rohwedder, K.5    Theuerkauf, A.6    Parikh, S.7
  • 44
    • 84876107265 scopus 로고    scopus 로고
    • The role of sodium-coupled glucose co-transporter 3 in the satiety effect of portal glucose sensing
    • Delaere, F., Duchampt, A., Mounien, L., Seyer, P., Duraffourd, C., Zitoun, C., et al. The role of sodium-coupled glucose co-transporter 3 in the satiety effect of portal glucose sensing. Mol Metab 2 (2012), 47–53.
    • (2012) Mol Metab , vol.2 , pp. 47-53
    • Delaere, F.1    Duchampt, A.2    Mounien, L.3    Seyer, P.4    Duraffourd, C.5    Zitoun, C.6
  • 45
    • 4644360065 scopus 로고    scopus 로고
    • Regulation of glucose transporter SGLT1 by ubiquitin ligase Nedd4-2 and kinases SGK1, SGK3, and PKB
    • Dieter, M., Palmada, M., Rajamanickam, J., Aydin, A., Busjahn, A., Boehmer, C.,.. Lang, F., Regulation of glucose transporter SGLT1 by ubiquitin ligase Nedd4-2 and kinases SGK1, SGK3, and PKB. Obes Res 12 (2004), 862–870.
    • (2004) Obes Res , vol.12 , pp. 862-870
    • Dieter, M.1    Palmada, M.2    Rajamanickam, J.3    Aydin, A.4    Busjahn, A.5    Boehmer, C.6    Lang, F.7
  • 46
    • 84930902626 scopus 로고    scopus 로고
    • Selective sodium-dependent glucose transporter 1 inhibitors block glucose absorption and impair glucose-dependent insulinotropic peptide release
    • Dobbins, R.L., Greenway, F.L., Chen, L., Liu, Y., Breed, S.L., Andrews, S.M., Wald, J.A., et al. Selective sodium-dependent glucose transporter 1 inhibitors block glucose absorption and impair glucose-dependent insulinotropic peptide release. Am J Physiol Gastrointest Liver Physiol 308 (2015), G946–G954.
    • (2015) Am J Physiol Gastrointest Liver Physiol , vol.308 , pp. G946-G954
    • Dobbins, R.L.1    Greenway, F.L.2    Chen, L.3    Liu, Y.4    Breed, S.L.5    Andrews, S.M.6    Wald, J.A.7
  • 48
    • 12744273119 scopus 로고    scopus 로고
    • Luminal leptin induces rapid inhibition of active intestinal absorption of glucose mediated by sodium-glucose cotransporter 1
    • Ducroc, R., Guilmeau, S., Akasbi, K., Devaud, H., Buyse, M., Bado, A., Luminal leptin induces rapid inhibition of active intestinal absorption of glucose mediated by sodium-glucose cotransporter 1. Diabetes 54 (2005), 348–354.
    • (2005) Diabetes , vol.54 , pp. 348-354
    • Ducroc, R.1    Guilmeau, S.2    Akasbi, K.3    Devaud, H.4    Buyse, M.5    Bado, A.6
  • 54
    • 84964608804 scopus 로고    scopus 로고
    • Shift to fatty substrates utilization in response to sodium-glucose co-transporter-2 inhibition in nondiabetic subjects and type 2 diabetic patients
    • Ferrannini, E., Baldi, S., Frascerra, S., Astiarraga, B., Heise, T., Bizzotto, R., et al. Shift to fatty substrates utilization in response to sodium-glucose co-transporter-2 inhibition in nondiabetic subjects and type 2 diabetic patients. Diabetes 65 (2016), 1190–1195.
    • (2016) Diabetes , vol.65 , pp. 1190-1195
    • Ferrannini, E.1    Baldi, S.2    Frascerra, S.3    Astiarraga, B.4    Heise, T.5    Bizzotto, R.6
  • 55
    • 84893872877 scopus 로고    scopus 로고
    • Metabolic response to sodium-glucose cotransporter 2 inhibition in type 2 diabetic patients
    • Ferrannini, E., Muscelli, E., Frascerra, S., Baldi, S., Mari, A., Heise, T., et al. Metabolic response to sodium-glucose cotransporter 2 inhibition in type 2 diabetic patients. J Clin Invest 124 (2014), 499–508.
    • (2014) J Clin Invest , vol.124 , pp. 499-508
    • Ferrannini, E.1    Muscelli, E.2    Frascerra, S.3    Baldi, S.4    Mari, A.5    Heise, T.6
  • 56
    • 0031034371 scopus 로고    scopus 로고
    • Regulation of intestinal sugar transport
    • Ferraris, R.P., Diamond, J., Regulation of intestinal sugar transport. Physiol Rev 77 (1997), 257–302.
    • (1997) Physiol Rev , vol.77 , pp. 257-302
    • Ferraris, R.P.1    Diamond, J.2
  • 57
    • 77955065720 scopus 로고    scopus 로고
    • High-normal serum uric acid increases risk of early progressive renal function loss in type 1 diabetes: Results of a 6-year follow-up
    • Ficociello, L.H., Rosolowsky, E.T., Niewczas, M.A., Maselli, N.J., Weinberg, J.M., Aschengrau, A., et al. High-normal serum uric acid increases risk of early progressive renal function loss in type 1 diabetes: Results of a 6-year follow-up. Diabetes Care 33 (2010), 1337–1343.
    • (2010) Diabetes Care , vol.33 , pp. 1337-1343
    • Ficociello, L.H.1    Rosolowsky, E.T.2    Niewczas, M.A.3    Maselli, N.J.4    Weinberg, J.M.5    Aschengrau, A.6
  • 58
    • 70350674915 scopus 로고    scopus 로고
    • Novel shuttling domain in a regulator (RSC1A1) of transporter SGLT1 steers cell cycle-dependent nuclear location
    • Filatova, A., Leyerer, M., Gorboulev, V., Chintalapati, C., Reinders, Y., Müller, T.D., et al. Novel shuttling domain in a regulator (RSC1A1) of transporter SGLT1 steers cell cycle-dependent nuclear location. Traffic 10 (2009), 1599–1618.
    • (2009) Traffic , vol.10 , pp. 1599-1618
    • Filatova, A.1    Leyerer, M.2    Gorboulev, V.3    Chintalapati, C.4    Reinders, Y.5    Müller, T.D.6
  • 59
    • 33748328212 scopus 로고    scopus 로고
    • Luminal glucose sensing in the rat intestine has characteristics of a sodium-glucose transporter
    • Freeman, S.L., Bohan, D., Darcel, N., Raybould, H.E., Luminal glucose sensing in the rat intestine has characteristics of a sodium-glucose transporter. Am J Physiol Gastrointest Liver Physiol 291 (2006), G439–G445.
    • (2006) Am J Physiol Gastrointest Liver Physiol , vol.291 , pp. G439-G445
    • Freeman, S.L.1    Bohan, D.2    Darcel, N.3    Raybould, H.E.4
  • 60
    • 84899904943 scopus 로고    scopus 로고
    • Renal sodium glucose cotransporter 2 inhibitors as a novel therapeutic approach to treatment of type 2 diabetes: Clinical data and mechanism of action
    • Fujita, Y., Inagaki, N., Renal sodium glucose cotransporter 2 inhibitors as a novel therapeutic approach to treatment of type 2 diabetes: Clinical data and mechanism of action. J Diabetes Investig 5 (2014), 265–275.
    • (2014) J Diabetes Investig , vol.5 , pp. 265-275
    • Fujita, Y.1    Inagaki, N.2
  • 61
    • 0031742335 scopus 로고    scopus 로고
    • Increased intestinal glucose absorption and postprandial hyperglycaemia at the early step of glucose intolerance in Otsuka Long-Evans Tokushima fatty rats
    • Fujita, Y., Kojima, H., Hidaka, H., Fujimiya, M., Kashiwagi, A., Kikkawa, R., Increased intestinal glucose absorption and postprandial hyperglycaemia at the early step of glucose intolerance in Otsuka Long-Evans Tokushima fatty rats. Diabetologia 41 (1998), 1459–1466.
    • (1998) Diabetologia , vol.41 , pp. 1459-1466
    • Fujita, Y.1    Kojima, H.2    Hidaka, H.3    Fujimiya, M.4    Kashiwagi, A.5    Kikkawa, R.6
  • 62
    • 84867847742 scopus 로고    scopus 로고
    • Structure–activity relationship studies of 4-benzyl-1H-pyrazol-3-yl beta-D-glucopyranoside derivatives as potent and selective sodium glucose co-transporter 1 (SGLT1) inhibitors with therapeutic activity on postprandial hyperglycemia
    • Fushimi, N., Fujikura, H., Shiohara, H., Teranishi, H., Shimizu, K., Yonekubo, S., et al. Structure–activity relationship studies of 4-benzyl-1H-pyrazol-3-yl beta-D-glucopyranoside derivatives as potent and selective sodium glucose co-transporter 1 (SGLT1) inhibitors with therapeutic activity on postprandial hyperglycemia. Bioorg Med Chem 20 (2012), 6598–6612.
    • (2012) Bioorg Med Chem , vol.20 , pp. 6598-6612
    • Fushimi, N.1    Fujikura, H.2    Shiohara, H.3    Teranishi, H.4    Shimizu, K.5    Yonekubo, S.6
  • 63
    • 84907659467 scopus 로고    scopus 로고
    • Positron emission tomography (PET) in oncology
    • Gallamini, A., Zwarthoed, C., Borra, A., Positron emission tomography (PET) in oncology. Cancers (Basel) 6 (2014), 1821–1889.
    • (2014) Cancers (Basel) , vol.6 , pp. 1821-1889
    • Gallamini, A.1    Zwarthoed, C.2    Borra, A.3
  • 64
    • 84977633501 scopus 로고    scopus 로고
    • Once daily administration of the SGLT2 inhibitor, empagliflozin, attenuates markers of renal fibrosis without improving albuminuria in diabetic db/db mice
    • Gallo, L.A., Ward, M.S., Fotheringham, A.K., Zhuang, A., Borg, D.J., Flemming, N.B., et al. Once daily administration of the SGLT2 inhibitor, empagliflozin, attenuates markers of renal fibrosis without improving albuminuria in diabetic db/db mice. Sci Rep, 6, 2016, 26428.
    • (2016) Sci Rep , vol.6 , pp. 26428
    • Gallo, L.A.1    Ward, M.S.2    Fotheringham, A.K.3    Zhuang, A.4    Borg, D.J.5    Flemming, N.B.6
  • 65
    • 84923527667 scopus 로고    scopus 로고
    • Probing SGLT2 as a therapeutic target for diabetes: Basic physiology and consequences
    • Gallo, L.A., Wright, E.M., Vallon, V., Probing SGLT2 as a therapeutic target for diabetes: Basic physiology and consequences. Diab Vasc Dis Res 12 (2015), 78–89.
    • (2015) Diab Vasc Dis Res , vol.12 , pp. 78-89
    • Gallo, L.A.1    Wright, E.M.2    Vallon, V.3
  • 66
    • 57749111596 scopus 로고    scopus 로고
    • Nutrient transporters in cancer: Relevance to Warburg hypothesis and beyond
    • Ganapathy, V., Thangaraju, M., Prasad, P.D., Nutrient transporters in cancer: Relevance to Warburg hypothesis and beyond. Pharmacol Ther 121 (2009), 29–40.
    • (2009) Pharmacol Ther , vol.121 , pp. 29-40
    • Ganapathy, V.1    Thangaraju, M.2    Prasad, P.D.3
  • 67
    • 84888798201 scopus 로고    scopus 로고
    • Tumor glycolysis as a target for cancer therapy: Progress and prospects
    • Ganapathy-Kanniappan, S., Geschwind, J.F., Tumor glycolysis as a target for cancer therapy: Progress and prospects. Mol Cancer, 12, 2013, 152.
    • (2013) Mol Cancer , vol.12 , pp. 152
    • Ganapathy-Kanniappan, S.1    Geschwind, J.F.2
  • 68
    • 84905238756 scopus 로고    scopus 로고
    • The SGLT2 inhibitor empagliflozin ameliorates early features of diabetic nephropathy in BTBR ob/ob type 2 diabetic mice with and without hypertension
    • Gembardt, F., Bartaun, C., Jarzebska, N., Mayoux, E., Todorov, V.T., Hohenstein, B., Hugo, C., The SGLT2 inhibitor empagliflozin ameliorates early features of diabetic nephropathy in BTBR ob/ob type 2 diabetic mice with and without hypertension. Am J Physiol Renal Physiol 307 (2014), F317–F325.
    • (2014) Am J Physiol Renal Physiol , vol.307 , pp. F317-F325
    • Gembardt, F.1    Bartaun, C.2    Jarzebska, N.3    Mayoux, E.4    Todorov, V.T.5    Hohenstein, B.6    Hugo, C.7
  • 71
    • 0023179755 scopus 로고
    • Intravenous but not intragastric urogastrone-EGF is trophic to the intestine of parenterally fed rats
    • Goodlad, R.A., Wilson, T.J., Lenton, W., Gregory, H., McCullagh, K.G., Wright, N.A., Intravenous but not intragastric urogastrone-EGF is trophic to the intestine of parenterally fed rats. Gut 28 (1987), 573–582.
    • (1987) Gut , vol.28 , pp. 573-582
    • Goodlad, R.A.1    Wilson, T.J.2    Lenton, W.3    Gregory, H.4    McCullagh, K.G.5    Wright, N.A.6
  • 72
    • 84555186977 scopus 로고    scopus 로고
    • +-D-glucose cotransporter SGLT1 is pivotal for intestinal glucose absorption and glucose-dependent incretin secretion
    • +-D-glucose cotransporter SGLT1 is pivotal for intestinal glucose absorption and glucose-dependent incretin secretion. Diabetes 61 (2012), 187–196.
    • (2012) Diabetes , vol.61 , pp. 187-196
    • Gorboulev, V.1    Schürmann, A.2    Vallon, V.3    Kipp, H.4    Jaschke, A.5    Klessen, D.6
  • 73
    • 0242391821 scopus 로고    scopus 로고
    • Simple-sugar meals target GLUT2 at enterocyte apical membranes to improve sugar absorption: a study in GLUT2-null mice
    • Gouyon, F., Caillaud, L., Carrière, V., Klein, C., Dalet, V., Citadelle, D., et al. Simple-sugar meals target GLUT2 at enterocyte apical membranes to improve sugar absorption: a study in GLUT2-null mice. J Physiol 552 (2003), 823–832.
    • (2003) J Physiol , vol.552 , pp. 823-832
    • Gouyon, F.1    Caillaud, L.2    Carrière, V.3    Klein, C.4    Dalet, V.5    Citadelle, D.6
  • 74
    • 83655184724 scopus 로고    scopus 로고
    • Empagliflozin, a novel selective sodium glucose cotransporter-2 (SGLT-2) inhibitor: characterisation and comparison with other SGLT-2 inhibitors
    • Grempler, R., Thomas, L., Eckhardt, M., Himmelsbach, F., Sauer, A., Sharp, D.E., et al. Empagliflozin, a novel selective sodium glucose cotransporter-2 (SGLT-2) inhibitor: characterisation and comparison with other SGLT-2 inhibitors. Diabetes Obes Metab 14 (2012), 83–90.
    • (2012) Diabetes Obes Metab , vol.14 , pp. 83-90
    • Grempler, R.1    Thomas, L.2    Eckhardt, M.3    Himmelsbach, F.4    Sauer, A.5    Sharp, D.E.6
  • 75
    • 33846856711 scopus 로고    scopus 로고
    • Alpha-cells of the endocrine pancreas: 35 Years of research but the enigma remains
    • Gromada, J., Franklin, I., Wollheim, C.B., Alpha-cells of the endocrine pancreas: 35 Years of research but the enigma remains. Endocr Rev 28 (2007), 84–116.
    • (2007) Endocr Rev , vol.28 , pp. 84-116
    • Gromada, J.1    Franklin, I.2    Wollheim, C.B.3
  • 76
    • 84655170171 scopus 로고    scopus 로고
    • Overexpression of SGLT1 and EGFR in colorectal cancer showing a correlation with the prognosis
    • Guo, G.F., Cai, Y.C., Zhang, B., Xu, R.H., Qiu, H.J., Xia, L.P., et al. Overexpression of SGLT1 and EGFR in colorectal cancer showing a correlation with the prognosis. Med Oncol 28 (2011), S197–S203.
    • (2011) Med Oncol , vol.28 , pp. S197-S203
    • Guo, G.F.1    Cai, Y.C.2    Zhang, B.3    Xu, R.H.4    Qiu, H.J.5    Xia, L.P.6
  • 77
    • 0016032989 scopus 로고
    • Glucose reabsorption from bile. Evidence for a biliohepatic circulation
    • Guzelian, P., Boyer, J.L., Glucose reabsorption from bile. Evidence for a biliohepatic circulation. J Clin Invest 53 (1974), 526–535.
    • (1974) J Clin Invest , vol.53 , pp. 526-535
    • Guzelian, P.1    Boyer, J.L.2
  • 78
    • 48249146624 scopus 로고    scopus 로고
    • Dapagliflozin, a selective SGLT2 inhibitor, improves glucose homeostasis in normal and diabetic rats
    • Han, S., Hagan, D.L., Taylor, J.R., Xin, L., Meng, W., Biller, S.A., et al. Dapagliflozin, a selective SGLT2 inhibitor, improves glucose homeostasis in normal and diabetic rats. Diabetes 57 (2008), 1723–1729.
    • (2008) Diabetes , vol.57 , pp. 1723-1729
    • Han, S.1    Hagan, D.L.2    Taylor, J.R.3    Xin, L.4    Meng, W.5    Biller, S.A.6
  • 80
    • 80555154280 scopus 로고    scopus 로고
    • High glucose promotes pancreatic cancer cell proliferation via the induction of EGF expression and transactivation of EGFR
    • Han, L., Ma, Q., Li, J., Liu, H., Li, W., Ma, G., et al. High glucose promotes pancreatic cancer cell proliferation via the induction of EGF expression and transactivation of EGFR. PLoS One, 6, 2011, e27074.
    • (2011) PLoS One , vol.6
    • Han, L.1    Ma, Q.2    Li, J.3    Liu, H.4    Li, W.5    Ma, G.6
  • 81
    • 84864276800 scopus 로고    scopus 로고
    • Coexpression of SGLT1 and EGFR is associated with tumor differentiation in oral squamous cell carcinoma
    • Hanabata, Y., Nakajima, Y., Morita, K., Kayamori, K., Omura, K., Coexpression of SGLT1 and EGFR is associated with tumor differentiation in oral squamous cell carcinoma. Odontology 100 (2011), 156–163.
    • (2011) Odontology , vol.100 , pp. 156-163
    • Hanabata, Y.1    Nakajima, Y.2    Morita, K.3    Kayamori, K.4    Omura, K.5
  • 82
    • 84917742055 scopus 로고    scopus 로고
    • Postprandial dynamics of plasma glucose, insulin, and glucagon in patients with type 2 diabetes treated with saxagliptin plus dapagliflozin add-on to metformin therapy
    • Hansen, L., Iqbal, N., Ekholm, E., Cook, W., Hirshberg, B., Postprandial dynamics of plasma glucose, insulin, and glucagon in patients with type 2 diabetes treated with saxagliptin plus dapagliflozin add-on to metformin therapy. Endocr Pract 20 (2014), 1187–1197.
    • (2014) Endocr Pract , vol.20 , pp. 1187-1197
    • Hansen, L.1    Iqbal, N.2    Ekholm, E.3    Cook, W.4    Hirshberg, B.5
  • 83
    • 67649392260 scopus 로고    scopus 로고
    • The development of glucose intolerance after focal cerebral ischemia participates in subsequent neuronal damage
    • Harada, S., Fujita, W.H., Shichi, K., Tokuyama, S., The development of glucose intolerance after focal cerebral ischemia participates in subsequent neuronal damage. Brain Res 1279 (2009), 174–181.
    • (2009) Brain Res , vol.1279 , pp. 174-181
    • Harada, S.1    Fujita, W.H.2    Shichi, K.3    Tokuyama, S.4
  • 85
    • 84901455931 scopus 로고    scopus 로고
    • Empagliflozin as add-on to metformin in patients with type 2 diabetes: A 24-week, randomized, double-blind, placebo-controlled trial
    • Haring, H.U., Merker, L., Seewaldt-Becker, E., Weimer, M., Meinicke, T., Broedl, U.C., Woerle, H.J., Empagliflozin as add-on to metformin in patients with type 2 diabetes: A 24-week, randomized, double-blind, placebo-controlled trial. Diabetes Care 37 (2014), 1650–1659.
    • (2014) Diabetes Care , vol.37 , pp. 1650-1659
    • Haring, H.U.1    Merker, L.2    Seewaldt-Becker, E.3    Weimer, M.4    Meinicke, T.5    Broedl, U.C.6    Woerle, H.J.7
  • 86
    • 84875123211 scopus 로고    scopus 로고
    • The ABCs of membrane transporters in health and disease (SLC series): Introduction
    • Hediger, M.A., Clémençon, B., Burrier, R.E., Bruford, E.A., The ABCs of membrane transporters in health and disease (SLC series): Introduction. Mol Asp Med 34 (2013), 95–107.
    • (2013) Mol Asp Med , vol.34 , pp. 95-107
    • Hediger, M.A.1    Clémençon, B.2    Burrier, R.E.3    Bruford, E.A.4
  • 88
    • 0028863503 scopus 로고
    • Overexpression of glucose transporters in rat mesangial cells cultured in a normal glucose milieu mimics the diabetic phenotype
    • Heilig, C.W., Concepcion, L.A., Riser, B.L., Freytag, S.O., Zhu, M., Cortes, P., Overexpression of glucose transporters in rat mesangial cells cultured in a normal glucose milieu mimics the diabetic phenotype. J Clin Invest 96 (1995), 1802–1814.
    • (1995) J Clin Invest , vol.96 , pp. 1802-1814
    • Heilig, C.W.1    Concepcion, L.A.2    Riser, B.L.3    Freytag, S.O.4    Zhu, M.5    Cortes, P.6
  • 89
    • 84860218907 scopus 로고    scopus 로고
    • Dapagliflozin, metformin XR, or both: Initial pharmacotherapy for type 2 diabetes, a randomised controlled trial
    • Henry, R.R., Murray, A.V., Marmolejo, M.H., Hennicken, D., Ptaszynska, A., List, J.F., Dapagliflozin, metformin XR, or both: Initial pharmacotherapy for type 2 diabetes, a randomised controlled trial. Int J Clin Pract 66 (2012), 446–456.
    • (2012) Int J Clin Pract , vol.66 , pp. 446-456
    • Henry, R.R.1    Murray, A.V.2    Marmolejo, M.H.3    Hennicken, D.4    Ptaszynska, A.5    List, J.F.6
  • 90
    • 84930580133 scopus 로고    scopus 로고
    • Glucuretic effects and renal safety of dapagliflozin in patients with type 2 diabetes
    • Hinnen, D., Glucuretic effects and renal safety of dapagliflozin in patients with type 2 diabetes. Ther Adv Endocrinol Metab 6 (2015), 92–102.
    • (2015) Ther Adv Endocrinol Metab , vol.6 , pp. 92-102
    • Hinnen, D.1
  • 91
    • 0032486248 scopus 로고    scopus 로고
    • Cholecystokinin decreases intestinal hexose absorption by a parallel reduction in SGLT1 abundance in the brush-border membrane
    • Hirsh, A.J., Cheeseman, C.I., Cholecystokinin decreases intestinal hexose absorption by a parallel reduction in SGLT1 abundance in the brush-border membrane. J Biol Chem 273 (1998), 14545–14549.
    • (1998) J Biol Chem , vol.273 , pp. 14545-14549
    • Hirsh, A.J.1    Cheeseman, C.I.2
  • 92
    • 35748957503 scopus 로고    scopus 로고
    • The physiology of glucagon-like peptide 1
    • Holst, J.J., The physiology of glucagon-like peptide 1. Physiol Rev 87 (2007), 1409–1439.
    • (2007) Physiol Rev , vol.87 , pp. 1409-1439
    • Holst, J.J.1
  • 94
    • 27944443159 scopus 로고    scopus 로고
    • Sodium-dependent glucose transporter reduces peroxynitrite and cell injury caused by cisplatin in renal tubular epithelial cells
    • Ikari, A., Nagatani, Y., Tsukimoto, M., Harada, H., Miwa, M., Takagi, K., Sodium-dependent glucose transporter reduces peroxynitrite and cell injury caused by cisplatin in renal tubular epithelial cells. Biochim Biophys Acta 1717 (2005), 109–117.
    • (2005) Biochim Biophys Acta , vol.1717 , pp. 109-117
    • Ikari, A.1    Nagatani, Y.2    Tsukimoto, M.3    Harada, H.4    Miwa, M.5    Takagi, K.6
  • 95
    • 0037031858 scopus 로고    scopus 로고
    • Up-regulation of sodium-dependent glucose transporter by interaction with heat shock protein 70
    • Ikari, A., Nakano, M., Kawano, K., Suketa, Y., Up-regulation of sodium-dependent glucose transporter by interaction with heat shock protein 70. J Biol Chem 277 (2002), 33338–33343.
    • (2002) J Biol Chem , vol.277 , pp. 33338-33343
    • Ikari, A.1    Nakano, M.2    Kawano, K.3    Suketa, Y.4
  • 96
    • 0034820481 scopus 로고    scopus 로고
    • SGLT gene expression in primary lung cancers and their metastatic lesions
    • Ishikawa, N., Oguri, T., Isobe, T., Fujitaka, K., Kohno, N., SGLT gene expression in primary lung cancers and their metastatic lesions. Jpn J Cancer Res 92 (2001), 874–879.
    • (2001) Jpn J Cancer Res , vol.92 , pp. 874-879
    • Ishikawa, N.1    Oguri, T.2    Isobe, T.3    Fujitaka, K.4    Kohno, N.5
  • 97
    • 84896701131 scopus 로고    scopus 로고
    • Dapagliflozin is effective as add-on therapy to sitagliptin with or without metformin: a 24-week, multicenter, randomized, double-blind, placebo-controlled study
    • Jabbour, S.A., Hardy, E., Sugg, J., Parikh, S., Dapagliflozin is effective as add-on therapy to sitagliptin with or without metformin: a 24-week, multicenter, randomized, double-blind, placebo-controlled study. Diabetes Care 37 (2014), 740–750.
    • (2014) Diabetes Care , vol.37 , pp. 740-750
    • Jabbour, S.A.1    Hardy, E.2    Sugg, J.3    Parikh, S.4
  • 98
    • 84957581904 scopus 로고    scopus 로고
    • Impact of reduced renal function on the glucose-lowering effects of luseogliflozin, a selective SGLT2 inhibitor, assessed by continuous glucose monitoring in Japanese patients with type 2 diabetes mellitus
    • Jinnouchi, H., Nozaki, K., Watase, H., Omiya, H., Sakai, S., Samukawa, Y., Impact of reduced renal function on the glucose-lowering effects of luseogliflozin, a selective SGLT2 inhibitor, assessed by continuous glucose monitoring in Japanese patients with type 2 diabetes mellitus. Adv Ther 33 (2016), 460–479.
    • (2016) Adv Ther , vol.33 , pp. 460-479
    • Jinnouchi, H.1    Nozaki, K.2    Watase, H.3    Omiya, H.4    Sakai, S.5    Samukawa, Y.6
  • 99
    • 34249929950 scopus 로고    scopus 로고
    • Development of diabetes in obese, insulin-resistant mice: essential role of dietary carbohydrate in beta cell destruction
    • Jurgens, H.S., Neschen, S., Ortmann, S., Scherneck, S., Schmolz, K., Schuler, G., et al. Development of diabetes in obese, insulin-resistant mice: essential role of dietary carbohydrate in beta cell destruction. Diabetologia 50 (2007), 1481–1489.
    • (2007) Diabetologia , vol.50 , pp. 1481-1489
    • Jurgens, H.S.1    Neschen, S.2    Ortmann, S.3    Scherneck, S.4    Schmolz, K.5    Schuler, G.6
  • 100
    • 0030851867 scopus 로고    scopus 로고
    • Overexpression of GLUT2 gene in renal proximal tubules of diabetic Zucker rats
    • Kamran, M., Peterson, R.G., Dominguez, J.H., Overexpression of GLUT2 gene in renal proximal tubules of diabetic Zucker rats. J Am Soc Nephrol 8 (1997), 943–948.
    • (1997) J Am Soc Nephrol , vol.8 , pp. 943-948
    • Kamran, M.1    Peterson, R.G.2    Dominguez, J.H.3
  • 101
    • 0028044629 scopus 로고
    • +/glucose cotransporter SGLT2. Delineation of the major renal reabsorptive mechanism of D-glucose
    • +/glucose cotransporter SGLT2. Delineation of the major renal reabsorptive mechanism of D-glucose. J Clin Invest 93 (1994), 397–404.
    • (1994) J Clin Invest , vol.93 , pp. 397-404
    • Kanai, Y.1    Lee, W.-S.2    You, G.3    Brown, D.4    Hediger, M.A.5
  • 102
    • 1442276966 scopus 로고    scopus 로고
    • Physiological and molecular characteristics of rat hypothalamic ventromedial nucleus glucosensing neurons
    • Kang, L., Routh, V.H., Kuzhikandathil, E.V., Gaspers, L.D., Levin, B.E., Physiological and molecular characteristics of rat hypothalamic ventromedial nucleus glucosensing neurons. Diabetes 53 (2004), 549–559.
    • (2004) Diabetes , vol.53 , pp. 549-559
    • Kang, L.1    Routh, V.H.2    Kuzhikandathil, E.V.3    Gaspers, L.D.4    Levin, B.E.5
  • 103
    • 84955619589 scopus 로고    scopus 로고
    • Nuclear mechanisms of insulin resistance
    • Kang, S., Tsai, L.T., Rosen, E.D., Nuclear mechanisms of insulin resistance. Trends Cell Biol 26 (2016), 341–351.
    • (2016) Trends Cell Biol , vol.26 , pp. 341-351
    • Kang, S.1    Tsai, L.T.2    Rosen, E.D.3
  • 104
    • 84938710060 scopus 로고    scopus 로고
    • Expression of SGLT1 in human hearts and impairment of cardiac glucose uptake by phlorizin during ischemia–reperfusion injury in mice
    • Kashiwagi, Y., Nagoshi, T., Yoshino, T., Tanaka, T.D., Ito, K., Harada, T., et al. Expression of SGLT1 in human hearts and impairment of cardiac glucose uptake by phlorizin during ischemia–reperfusion injury in mice. PLoS One, 10, 2015, e0130605.
    • (2015) PLoS One , vol.10
    • Kashiwagi, Y.1    Nagoshi, T.2    Yoshino, T.3    Tanaka, T.D.4    Ito, K.5    Harada, T.6
  • 105
    • 48249101312 scopus 로고    scopus 로고
    • Role of Sp1 and HNF1 transcription factors in SGLT1 regulation during chronic intestinal inflammation
    • Kekuda, R., Saha, P., Sundaram, U., Role of Sp1 and HNF1 transcription factors in SGLT1 regulation during chronic intestinal inflammation. Am J Physiol Gastrointest Liver Physiol 294 (2008), G1354–G1361.
    • (2008) Am J Physiol Gastrointest Liver Physiol , vol.294 , pp. G1354-G1361
    • Kekuda, R.1    Saha, P.2    Sundaram, U.3
  • 106
    • 84959511891 scopus 로고    scopus 로고
    • The SGLT2 inhibitor empagliflozin improves insulin sensitivity in db/db mice both as monotherapy and in combination with linagliptin
    • Kern, M., Kloting, N., Mark, M., Mayoux, E., Klein, T., Bluher, M., The SGLT2 inhibitor empagliflozin improves insulin sensitivity in db/db mice both as monotherapy and in combination with linagliptin. Metabolism 65 (2016), 114–123.
    • (2016) Metabolism , vol.65 , pp. 114-123
    • Kern, M.1    Kloting, N.2    Mark, M.3    Mayoux, E.4    Klein, T.5    Bluher, M.6
  • 107
    • 84897394040 scopus 로고    scopus 로고
    • Long-term study of patients with type 2 diabetes and moderate renal impairment shows that dapagliflozin reduces weight and blood pressure but does not improve glycemic control
    • Kohan, D.E., Fioretto, P., Tang, W., List, J.F., Long-term study of patients with type 2 diabetes and moderate renal impairment shows that dapagliflozin reduces weight and blood pressure but does not improve glycemic control. Kidney Int 85 (2014), 962–971.
    • (2014) Kidney Int , vol.85 , pp. 962-971
    • Kohan, D.E.1    Fioretto, P.2    Tang, W.3    List, J.F.4
  • 108
    • 84878060305 scopus 로고    scopus 로고
    • Effects of a new SGLT2 inhibitor, luseogliflozin, on diabetic nephropathy in T2DN rats
    • Kojima, N., Williams, J.M., Takahashi, T., Miyata, N., Roman, R.J., Effects of a new SGLT2 inhibitor, luseogliflozin, on diabetic nephropathy in T2DN rats. J Pharmacol Exp Ther 345 (2013), 464–472.
    • (2013) J Pharmacol Exp Ther , vol.345 , pp. 464-472
    • Kojima, N.1    Williams, J.M.2    Takahashi, T.3    Miyata, N.4    Roman, R.J.5
  • 109
    • 84961615237 scopus 로고    scopus 로고
    • Ipragliflozin improves hepatic steatosis in obese mice and liver dysfunction in type 2 diabetic patients irrespective of body weight reduction
    • Komiya, C., Tsuchiya, K., Shiba, K., Miyachi, Y., Furuke, S., Shimazu, N., et al. Ipragliflozin improves hepatic steatosis in obese mice and liver dysfunction in type 2 diabetic patients irrespective of body weight reduction. PLoS One, 11, 2016, e0151511.
    • (2016) PLoS One , vol.11
    • Komiya, C.1    Tsuchiya, K.2    Shiba, K.3    Miyachi, Y.4    Furuke, S.5    Shimazu, N.6
  • 110
    • 67349275999 scopus 로고    scopus 로고
    • Dapagliflozin, a novel, selective SGLT2 inhibitor, improved glycemic control over 2 weeks in patients with type 2 diabetes mellitus
    • Komoroski, B., Vachharajani, N., Feng, Y., Li, L., Kornhauser, D., Pfister, M., Dapagliflozin, a novel, selective SGLT2 inhibitor, improved glycemic control over 2 weeks in patients with type 2 diabetes mellitus. Clin Pharmacol Ther 85 (2009), 513–519.
    • (2009) Clin Pharmacol Ther , vol.85 , pp. 513-519
    • Komoroski, B.1    Vachharajani, N.2    Feng, Y.3    Li, L.4    Kornhauser, D.5    Pfister, M.6
  • 111
    • 0035976973 scopus 로고    scopus 로고
    • The plasma membrane-associated protein RS1 decreases transcription of the transporter SGLT1 in confluent LLC-PK1 cells
    • Korn, T., Kühlkamp, T., Track, C., Schatz, I., Baumgarten, K., Gorboulev, V., Koepsell, H., The plasma membrane-associated protein RS1 decreases transcription of the transporter SGLT1 in confluent LLC-PK1 cells. J Biol Chem 276 (2001), 45330–45340.
    • (2001) J Biol Chem , vol.276 , pp. 45330-45340
    • Korn, T.1    Kühlkamp, T.2    Track, C.3    Schatz, I.4    Baumgarten, K.5    Gorboulev, V.6    Koepsell, H.7
  • 112
    • 84892477577 scopus 로고    scopus 로고
    • Empagliflozin improves glycaemic and weight control as add-on therapy to pioglitazone or pioglitazone plus metformin in patients with type 2 diabetes: a 24-week, randomized, placebo-controlled trial
    • Kovacs, C.S., Seshiah, V., Swallow, R., Jones, R., Rattunde, H., Woerle, H.J., Broedl, U.C., Empagliflozin improves glycaemic and weight control as add-on therapy to pioglitazone or pioglitazone plus metformin in patients with type 2 diabetes: a 24-week, randomized, placebo-controlled trial. Diabetes Obes Metab 16 (2014), 147–158.
    • (2014) Diabetes Obes Metab , vol.16 , pp. 147-158
    • Kovacs, C.S.1    Seshiah, V.2    Swallow, R.3    Jones, R.4    Rattunde, H.5    Woerle, H.J.6    Broedl, U.C.7
  • 113
    • 84924924178 scopus 로고    scopus 로고
    • The regulation of glucose metabolism: implications and considerations for the assessment of glucose homeostasis in rodents
    • Kowalski, G.M., Bruce, C.R., The regulation of glucose metabolism: implications and considerations for the assessment of glucose homeostasis in rodents. Am J Physiol Endocrinol Metab 307 (2014), E859–E871.
    • (2014) Am J Physiol Endocrinol Metab , vol.307 , pp. E859-E871
    • Kowalski, G.M.1    Bruce, C.R.2
  • 114
    • 84959342655 scopus 로고    scopus 로고
    • Patient considerations in type 2 diabetes — Role of combination dapagliflozin-metformin XR
    • Kuecker, C.M., Vivian, E.M., Patient considerations in type 2 diabetes — Role of combination dapagliflozin-metformin XR. Diabetes Metab Syndr Obes 9 (2016), 25–35.
    • (2016) Diabetes Metab Syndr Obes , vol.9 , pp. 25-35
    • Kuecker, C.M.1    Vivian, E.M.2
  • 115
    • 84877922239 scopus 로고    scopus 로고
    • Ipragliflozin and other sodium-glucose cotransporter-2 (SGLT2) inhibitors in the treatment of type 2 diabetes: preclinical and clinical data
    • Kurosaki, E., Ogasawara, H., Ipragliflozin and other sodium-glucose cotransporter-2 (SGLT2) inhibitors in the treatment of type 2 diabetes: preclinical and clinical data. Pharmacol Ther 139 (2013), 51–59.
    • (2013) Pharmacol Ther , vol.139 , pp. 51-59
    • Kurosaki, E.1    Ogasawara, H.2
  • 116
    • 84975266782 scopus 로고    scopus 로고
    • Benefits/risks of sodium-glucose co-transporter 2 inhibitor canagliflozin in women for the treatment of type 2 diabetes
    • Kushner, P., Benefits/risks of sodium-glucose co-transporter 2 inhibitor canagliflozin in women for the treatment of type 2 diabetes. Women's Health (Lond Engl) 12 (2016), 379–388.
    • (2016) Women's Health (Lond Engl) , vol.12 , pp. 379-388
    • Kushner, P.1
  • 117
    • 84862759133 scopus 로고    scopus 로고
    • Overexpression of SGLT1 is correlated with tumor development and poor prognosis of ovarian carcinoma
    • Lai, B., Xiao, Y., Pu, H., Cao, Q., Jing, H., Liu, X., Overexpression of SGLT1 is correlated with tumor development and poor prognosis of ovarian carcinoma. Arch Gynecol Obstet 285 (2012), 1455–1461.
    • (2012) Arch Gynecol Obstet , vol.285 , pp. 1455-1461
    • Lai, B.1    Xiao, Y.2    Pu, H.3    Cao, Q.4    Jing, H.5    Liu, X.6
  • 118
    • 84880850027 scopus 로고    scopus 로고
    • Dapagliflozin a glucose-regulating drug with diuretic properties in subjects with type 2 diabetes
    • Lambers Heerspink, H.J., de Zeeuw, D., Wie, L., Leslie, B., List, J., Dapagliflozin a glucose-regulating drug with diuretic properties in subjects with type 2 diabetes. Diabetes Obes Metab 15 (2013), 853–862.
    • (2013) Diabetes Obes Metab , vol.15 , pp. 853-862
    • Lambers Heerspink, H.J.1    de Zeeuw, D.2    Wie, L.3    Leslie, B.4    List, J.5
  • 119
    • 33749500123 scopus 로고    scopus 로고
    • (Patho)physiological significance of the serum- and glucocorticoid-inducible kinase isoforms
    • Lang, F., Bohmer, C., Palmada, M., Seebohm, G., Strutz-Seebohm, N., Vallon, V., (Patho)physiological significance of the serum- and glucocorticoid-inducible kinase isoforms. Physiol Rev 86 (2006), 1151–1178.
    • (2006) Physiol Rev , vol.86 , pp. 1151-1178
    • Lang, F.1    Bohmer, C.2    Palmada, M.3    Seebohm, G.4    Strutz-Seebohm, N.5    Vallon, V.6
  • 120
    • 84887997289 scopus 로고    scopus 로고
    • Efficacy and safety of canagliflozin compared with placebo and sitagliptin in patients with type 2 diabetes on background metformin monotherapy: A randomised trial
    • Lavalle-Gonzalez, F.J., Januszewicz, A., Davidson, J., Tong, C., Qiu, R., Canovatchel, W., Meininger, G., Efficacy and safety of canagliflozin compared with placebo and sitagliptin in patients with type 2 diabetes on background metformin monotherapy: A randomised trial. Diabetologia 56 (2013), 2582–2592.
    • (2013) Diabetologia , vol.56 , pp. 2582-2592
    • Lavalle-Gonzalez, F.J.1    Januszewicz, A.2    Davidson, J.3    Tong, C.4    Qiu, R.5    Canovatchel, W.6    Meininger, G.7
  • 121
    • 0028234548 scopus 로고
    • +/glucose cotransporter. Re-evaluation of function and distribution of expression
    • +/glucose cotransporter. Re-evaluation of function and distribution of expression. J Biol Chem 269 (1994), 12032–12039.
    • (1994) J Biol Chem , vol.269 , pp. 12032-12039
    • Lee, S.-W.1    Kanai, Y.2    Wells, R.G.3    Hediger, M.A.4
  • 122
    • 84924811717 scopus 로고    scopus 로고
    • Distinct action of α-glucosidase inhibitor miglitol on SGLT3, enteroendocrine cells, and GLP1 secretion
    • Lee, E.Y., Kaneko, S., Jutabha, P., Zhang, X., Seino, S., Jomori, T., et al. Distinct action of α-glucosidase inhibitor miglitol on SGLT3, enteroendocrine cells, and GLP1 secretion. J Endocrinol 224 (2015), 205–214.
    • (2015) J Endocrinol , vol.224 , pp. 205-214
    • Lee, E.Y.1    Kaneko, S.2    Jutabha, P.3    Zhang, X.4    Seino, S.5    Jomori, T.6
  • 123
    • 0000309353 scopus 로고    scopus 로고
    • +/glucose cotransporter (SGLT1) mRNA stability. Interaction of a nucleocytoplasmic protein with a regulatory domain in the 3′-untranslated region critical for stabilization
    • +/glucose cotransporter (SGLT1) mRNA stability. Interaction of a nucleocytoplasmic protein with a regulatory domain in the 3′-untranslated region critical for stabilization. J Biol Chem 275 (2000), 33998–34008.
    • (2000) J Biol Chem , vol.275 , pp. 33998-34008
    • Lee, W.Y.1    Loflin, P.2    Clancey, C.J.3    Peng, H.4    Lever, J.E.5
  • 124
    • 84940110139 scopus 로고    scopus 로고
    • Canagliflozin provides durable glycemic improvements and body weight reduction over 104 weeks versus glimepiride in patients with type 2 diabetes on metformin: a randomized, double-blind, phase 3 study
    • Leiter, L.A., Yoon, K.H., Arias, P., Langslet, G., Xie, J., Balis, D.A., et al. Canagliflozin provides durable glycemic improvements and body weight reduction over 104 weeks versus glimepiride in patients with type 2 diabetes on metformin: a randomized, double-blind, phase 3 study. Diabetes Care 38 (2015), 355–364.
    • (2015) Diabetes Care , vol.38 , pp. 355-364
    • Leiter, L.A.1    Yoon, K.H.2    Arias, P.3    Langslet, G.4    Xie, J.5    Balis, D.A.6
  • 125
    • 85006733634 scopus 로고    scopus 로고
    • SGK1 inhibitor reverses hyperglycemia partially through decreasing glucose absorption
    • Li, P., Hao, Y., Pan, F.H., Zhang, M., Ma, J.Q., Zhu, D.L., SGK1 inhibitor reverses hyperglycemia partially through decreasing glucose absorption. J Mol Endocrinol 56 (2016), 301–309, 10.1530/JME-15-0285.
    • (2016) J Mol Endocrinol , vol.56 , pp. 301-309
    • Li, P.1    Hao, Y.2    Pan, F.H.3    Zhang, M.4    Ma, J.Q.5    Zhu, D.L.6
  • 127
    • 84930580913 scopus 로고    scopus 로고
    • Update on long-term efficacy and safety of dapagliflozin in patients with type 2 diabetes mellitus
    • Liakos, A., Karagiannis, T., Bekiari, E., Boura, P., Tsapas, A., Update on long-term efficacy and safety of dapagliflozin in patients with type 2 diabetes mellitus. Ther Adv Endocrinol Metab 6 (2015), 61–67.
    • (2015) Ther Adv Endocrinol Metab , vol.6 , pp. 61-67
    • Liakos, A.1    Karagiannis, T.2    Bekiari, E.3    Boura, P.4    Tsapas, A.5
  • 128
    • 65349196064 scopus 로고    scopus 로고
    • Sodium-glucose cotransport inhibition with dapagliflozin in type 2 diabetes
    • List, J.F., Woo, V., Morales, E., Tang, W., Fiedorek, F.T., Sodium-glucose cotransport inhibition with dapagliflozin in type 2 diabetes. Diabetes Care 32 (2009), 650–657.
    • (2009) Diabetes Care , vol.32 , pp. 650-657
    • List, J.F.1    Woo, V.2    Morales, E.3    Tang, W.4    Fiedorek, F.T.5
  • 129
    • 84902240389 scopus 로고    scopus 로고
    • Luseogliflozin: First global approval
    • Markham, A., Elkinson, S., Luseogliflozin: First global approval. Drugs 74 (2014), 945–950.
    • (2014) Drugs , vol.74 , pp. 945-950
    • Markham, A.1    Elkinson, S.2
  • 130
    • 0345327784 scopus 로고    scopus 로고
    • Diabetes increases facilitative glucose uptake and GLUT2 expression at the rat proximal tubule brush border membrane
    • Marks, J., Carvou, N.J.C., Debnam, E.S., Srai, S.K., Unwin, R.J., Diabetes increases facilitative glucose uptake and GLUT2 expression at the rat proximal tubule brush border membrane. J Physiol 553 (2003), 137–145.
    • (2003) J Physiol , vol.553 , pp. 137-145
    • Marks, J.1    Carvou, N.J.C.2    Debnam, E.S.3    Srai, S.K.4    Unwin, R.J.5
  • 132
    • 0031887925 scopus 로고    scopus 로고
    • +-dependent and phlorizin-inhibitable transport of glucose and cycasin in brain endothelial cells
    • +-dependent and phlorizin-inhibitable transport of glucose and cycasin in brain endothelial cells. J Neurochem 70 (1998), 772–777.
    • (1998) J Neurochem , vol.70 , pp. 772-777
    • Matsuoka, T.1    Nishizaki, T.2    Kisby, G.E.3
  • 133
    • 37849031379 scopus 로고    scopus 로고
    • Measurements of rat and mouse gastrointestinal pH, fluid and lymphoid tissue, and implications for in-vivo experiments
    • McConnell, E.L., Basit, A.W., Murdan, S., Measurements of rat and mouse gastrointestinal pH, fluid and lymphoid tissue, and implications for in-vivo experiments. J Pharm Pharmacol 60 (2008), 63–70.
    • (2008) J Pharm Pharmacol , vol.60 , pp. 63-70
    • McConnell, E.L.1    Basit, A.W.2    Murdan, S.3
  • 134
    • 1842410679 scopus 로고    scopus 로고
    • Epidermal growth factor up-regulates sodium-glucose cotransport in enterocyte models in the presence of cholera toxin
    • Mehta, D.I., Horvath, K., Chanasongcram, S., Hill, I.D., Panigrahi, P., Epidermal growth factor up-regulates sodium-glucose cotransport in enterocyte models in the presence of cholera toxin. Parenter Enteral Nutr 21 (1997), 185–191.
    • (1997) Parenter Enteral Nutr , vol.21 , pp. 185-191
    • Mehta, D.I.1    Horvath, K.2    Chanasongcram, S.3    Hill, I.D.4    Panigrahi, P.5
  • 135
    • 41649087328 scopus 로고    scopus 로고
    • Discovery of dapagliflozin: A potent, selective renal sodium-dependent glucose cotransporter 2 (SGLT2) inhibitor for the treatment of type 2 diabetes
    • Meng, W., Ellsworth, B.A., Nirschl, A.A., McCann, P.J., Patel, M., Girotra, R.N., et al. Discovery of dapagliflozin: A potent, selective renal sodium-dependent glucose cotransporter 2 (SGLT2) inhibitor for the treatment of type 2 diabetes. J Med Chem 51 (2008), 1145–1149.
    • (2008) J Med Chem , vol.51 , pp. 1145-1149
    • Meng, W.1    Ellsworth, B.A.2    Nirschl, A.A.3    McCann, P.J.4    Patel, M.5    Girotra, R.N.6
  • 136
    • 84941702063 scopus 로고    scopus 로고
    • Prevalence of and trends in diabetes among adults in the United States, 1988–2012
    • Menke, A., Casagrande, S., Geiss, L., Cowie, C.C., Prevalence of and trends in diabetes among adults in the United States, 1988–2012. JAMA 314 (2015), 1021–1029.
    • (2015) JAMA , vol.314 , pp. 1021-1029
    • Menke, A.1    Casagrande, S.2    Geiss, L.3    Cowie, C.C.4
  • 137
    • 84893827104 scopus 로고    scopus 로고
    • Dapagliflozin improves muscle insulin sensitivity but enhances endogenous glucose production
    • Merovci, A., Solis-Herrera, C., Daniele, G., Eldor, R., Fiorentino, T.V., Tripathy, D., et al. Dapagliflozin improves muscle insulin sensitivity but enhances endogenous glucose production. J Clin Invest 124 (2014), 509–514.
    • (2014) J Clin Invest , vol.124 , pp. 509-514
    • Merovci, A.1    Solis-Herrera, C.2    Daniele, G.3    Eldor, R.4    Fiorentino, T.V.5    Tripathy, D.6
  • 138
    • 84937525356 scopus 로고    scopus 로고
    • A comprehensive review of the pharmacodynamics of the SGLT2 inhibitor empagliflozin in animals and humans
    • Michel, M.C., Mayoux, E., Vallon, V., A comprehensive review of the pharmacodynamics of the SGLT2 inhibitor empagliflozin in animals and humans. Naunyn Schmiedeberg's Arch Pharmacol 388 (2015), 801–816.
    • (2015) Naunyn Schmiedeberg's Arch Pharmacol , vol.388 , pp. 801-816
    • Michel, M.C.1    Mayoux, E.2    Vallon, V.3
  • 139
    • 84973562609 scopus 로고    scopus 로고
    • Comparison between SGLT2 inhibitors and DPP4 inhibitors added to insulin therapy in type 2 diabetes: A systematic review with indirect comparison meta-analysis
    • Min, S.H., Yoon, J.H., Hahn, S., Cho, Y.M., Comparison between SGLT2 inhibitors and DPP4 inhibitors added to insulin therapy in type 2 diabetes: A systematic review with indirect comparison meta-analysis. Diabetes Metab Res Rev, 2016, 10.1002/dmrr.2818.
    • (2016) Diabetes Metab Res Rev
    • Min, S.H.1    Yoon, J.H.2    Hahn, S.3    Cho, Y.M.4
  • 140
    • 7244239341 scopus 로고    scopus 로고
    • A novel role for glucose 6-phosphatase in the small intestine in the control of glucose homeostasis
    • Mithieux, G., Rajas, F., Gautier-Stein, A., A novel role for glucose 6-phosphatase in the small intestine in the control of glucose homeostasis. J Biol Chem 279 (2004), 44231–44234.
    • (2004) J Biol Chem , vol.279 , pp. 44231-44234
    • Mithieux, G.1    Rajas, F.2    Gautier-Stein, A.3
  • 142
    • 84957709696 scopus 로고    scopus 로고
    • Sodium-glucose cotransporter inhibitors: Effects on renal and intestinal glucose transport: From bench to bedside
    • Mudaliar, S., Polidori, D., Zambrowicz, B., Henry, R.R., Sodium-glucose cotransporter inhibitors: Effects on renal and intestinal glucose transport: From bench to bedside. Diabetes Care 38 (2015), 2344–2353.
    • (2015) Diabetes Care , vol.38 , pp. 2344-2353
    • Mudaliar, S.1    Polidori, D.2    Zambrowicz, B.3    Henry, R.R.4
  • 143
    • 84875135352 scopus 로고    scopus 로고
    • The SLC2 (GLUT) family of membrane transporters
    • Mueckler, M., Thorens, B., The SLC2 (GLUT) family of membrane transporters. Mol Asp Med 34 (2013), 121–138.
    • (2013) Mol Asp Med , vol.34 , pp. 121-138
    • Mueckler, M.1    Thorens, B.2
  • 144
    • 84860183617 scopus 로고    scopus 로고
    • A novel approach to control hyperglycemia in type 2 diabetes: Sodium glucose co-transport (SGLT) inhibitors: Systematic review and meta-analysis of randomized trials
    • Musso, G., Gambino, R., Cassader, M., Pagano, G., A novel approach to control hyperglycemia in type 2 diabetes: Sodium glucose co-transport (SGLT) inhibitors: Systematic review and meta-analysis of randomized trials. Ann Med 44 (2012), 375–393.
    • (2012) Ann Med , vol.44 , pp. 375-393
    • Musso, G.1    Gambino, R.2    Cassader, M.3    Pagano, G.4
  • 145
    • 84884554260 scopus 로고    scopus 로고
    • Tofogliflozin, a novel sodium-glucose co-transporter 2 inhibitor, improves renal and pancreatic function in db/db mice
    • Nagata, T., Fukuzawa, T., Takeda, M., Fukazawa, M., Mori, T., Nihei, T., et al. Tofogliflozin, a novel sodium-glucose co-transporter 2 inhibitor, improves renal and pancreatic function in db/db mice. Br J Pharmacol 170 (2013), 519–531.
    • (2013) Br J Pharmacol , vol.170 , pp. 519-531
    • Nagata, T.1    Fukuzawa, T.2    Takeda, M.3    Fukazawa, M.4    Mori, T.5    Nihei, T.6
  • 146
    • 84908066747 scopus 로고    scopus 로고
    • Update on developments with SGLT2 inhibitors in the management of type 2 diabetes
    • Nauck, M.A., Update on developments with SGLT2 inhibitors in the management of type 2 diabetes. Drug Des Devel Ther 8 (2014), 1335–1380.
    • (2014) Drug Des Devel Ther , vol.8 , pp. 1335-1380
    • Nauck, M.A.1
  • 147
    • 80155124676 scopus 로고    scopus 로고
    • Dapagliflozin versus glipizide as add-on therapy in patients with type 2 diabetes who have inadequate glycemic control with metformin: A randomized, 52-week, double-blind, active-controlled noninferiority trial
    • Nauck, M.A., Del, P.S., Meier, J.J., Duran-Garcia, S., Rohwedder, K., Elze, M., Parikh, S.J., Dapagliflozin versus glipizide as add-on therapy in patients with type 2 diabetes who have inadequate glycemic control with metformin: A randomized, 52-week, double-blind, active-controlled noninferiority trial. Diabetes Care 34 (2011), 2015–2022.
    • (2011) Diabetes Care , vol.34 , pp. 2015-2022
    • Nauck, M.A.1    Del, P.S.2    Meier, J.J.3    Duran-Garcia, S.4    Rohwedder, K.5    Elze, M.6    Parikh, S.J.7
  • 148
    • 79952310049 scopus 로고    scopus 로고
    • Secretion of glucagon-like peptide-1 (GLP-1) in type 2 diabetes: What is up, what is down?
    • Nauck, M.A., Vardarli, I., Deacon, C.F., Holst, J.J., Meier, J.J., Secretion of glucagon-like peptide-1 (GLP-1) in type 2 diabetes: What is up, what is down?. Diabetologica 54 (2011), 10–18.
    • (2011) Diabetologica , vol.54 , pp. 10-18
    • Nauck, M.A.1    Vardarli, I.2    Deacon, C.F.3    Holst, J.J.4    Meier, J.J.5
  • 149
    • 84914144323 scopus 로고    scopus 로고
    • Durability of glycaemic efficacy over 2 years with dapagliflozin versus glipizide as add-on therapies in patients whose type 2 diabetes mellitus is inadequately controlled with metformin
    • Nauck, M.A., Del, P.S., Duran-Garcia, S., Rohwedder, K., Langkilde, A.M., Sugg, J., Parikh, S.J., Durability of glycaemic efficacy over 2 years with dapagliflozin versus glipizide as add-on therapies in patients whose type 2 diabetes mellitus is inadequately controlled with metformin. Diabetes Obes Metab 16 (2014), 1111–1120.
    • (2014) Diabetes Obes Metab , vol.16 , pp. 1111-1120
    • Nauck, M.A.1    Del, P.S.2    Duran-Garcia, S.3    Rohwedder, K.4    Langkilde, A.M.5    Sugg, J.6    Parikh, S.J.7
  • 150
    • 84882290089 scopus 로고    scopus 로고
    • Genital mycotic infections in patients with diabetes
    • Nyirjesy, P., Sobel, J.D., Genital mycotic infections in patients with diabetes. Postgrad Med 125 (2013), 33–46.
    • (2013) Postgrad Med , vol.125 , pp. 33-46
    • Nyirjesy, P.1    Sobel, J.D.2
  • 151
    • 84900823374 scopus 로고    scopus 로고
    • Genital mycotic infections with canagliflozin, a sodium glucose co-transporter 2 inhibitor, in patients with type 2 diabetes mellitus: a pooled analysis of clinical studies
    • Nyirjesy, P., Sobel, J.D., Fung, A., Mayer, C., Capuano, G., Ways, K., Usiskin, K., Genital mycotic infections with canagliflozin, a sodium glucose co-transporter 2 inhibitor, in patients with type 2 diabetes mellitus: a pooled analysis of clinical studies. Curr Med Res Opin 30 (2014), 1109–1119.
    • (2014) Curr Med Res Opin , vol.30 , pp. 1109-1119
    • Nyirjesy, P.1    Sobel, J.D.2    Fung, A.3    Mayer, C.4    Capuano, G.5    Ways, K.6    Usiskin, K.7
  • 152
    • 84959366596 scopus 로고    scopus 로고
    • Euglycemic diabetic ketoacidosis induced by SGLT2 inhibitors: Possible mechanism and contributing factors
    • Ogawa, W., Sakaguchi, K., Euglycemic diabetic ketoacidosis induced by SGLT2 inhibitors: Possible mechanism and contributing factors. J Diabetes Investig 7 (2016), 135–138.
    • (2016) J Diabetes Investig , vol.7 , pp. 135-138
    • Ogawa, W.1    Sakaguchi, K.2
  • 153
    • 84976371974 scopus 로고    scopus 로고
    • Interaction of the sodium/glucose cotransporter (SGLT) 2 inhibitor canagliflozin with SGLT1 and SGLT2
    • Ohgaki, R., Wei, L., Yamada, K., Hara, T., Kuriyama, C., Okuda, S., Interaction of the sodium/glucose cotransporter (SGLT) 2 inhibitor canagliflozin with SGLT1 and SGLT2. J Pharmacol Exp Ther 358 (2016), 94–102.
    • (2016) J Pharmacol Exp Ther , vol.358 , pp. 94-102
    • Ohgaki, R.1    Wei, L.2    Yamada, K.3    Hara, T.4    Kuriyama, C.5    Okuda, S.6
  • 154
    • 80052572117 scopus 로고    scopus 로고
    • 5a-Carba-b-D-glucopyranose derivatives as novel sodium-dependent glucose cotransporter 2 (SGLT2) inhibitors for the treatment of type 2 diabetes
    • Ohtake, Y., Sato, T., Matsuoka, H., Nishimoto, M., Taka, N., Takano, K., et al. 5a-Carba-b-D-glucopyranose derivatives as novel sodium-dependent glucose cotransporter 2 (SGLT2) inhibitors for the treatment of type 2 diabetes. Bioorg Med Chem 19 (2011), 5334–5341.
    • (2011) Bioorg Med Chem , vol.19 , pp. 5334-5341
    • Ohtake, Y.1    Sato, T.2    Matsuoka, H.3    Nishimoto, M.4    Taka, N.5    Takano, K.6
  • 155
    • 34547957993 scopus 로고    scopus 로고
    • Postprandial hyperglycemia/hyperlipidemia (postprandial dysmetabolism) is a cardiovascular risk factor
    • O'Keefe, J.H., Bell, D.S., Postprandial hyperglycemia/hyperlipidemia (postprandial dysmetabolism) is a cardiovascular risk factor. Am J Cardiol 100 (2007), 899–904.
    • (2007) Am J Cardiol , vol.100 , pp. 899-904
    • O'Keefe, J.H.1    Bell, D.S.2
  • 157
    • 84901198078 scopus 로고    scopus 로고
    • Blood pressure effects of sodium-glucose co-transport 2 (SGLT2) inhibitors
    • Oliva, R.V., Bakris, G.L., Blood pressure effects of sodium-glucose co-transport 2 (SGLT2) inhibitors. J Am Soc Hypertens 8 (2014), 330–339.
    • (2014) J Am Soc Hypertens , vol.8 , pp. 330-339
    • Oliva, R.V.1    Bakris, G.L.2
  • 158
    • 33845516690 scopus 로고    scopus 로고
    • Sodium-coupled glucose cotransporters contribute to hypothalamic glucose sensing
    • O'Malley, D., Reimann, F., Simpson, A.K., Gribble, F.M., Sodium-coupled glucose cotransporters contribute to hypothalamic glucose sensing. Diabetes 55 (2006), 3381–3386.
    • (2006) Diabetes , vol.55 , pp. 3381-3386
    • O'Malley, D.1    Reimann, F.2    Simpson, A.K.3    Gribble, F.M.4
  • 160
    • 51549090437 scopus 로고    scopus 로고
    • Sodium-dependent glucose transporter-1 as a novel immunological player in the intestinal mucosa
    • Palazzo, M., Gariboldi, S., Zanobbio, L., Selleri, S., Dusio, G.F., Mauro, V., et al. Sodium-dependent glucose transporter-1 as a novel immunological player in the intestinal mucosa. J Immunol 181 (2008), 3126–3136.
    • (2008) J Immunol , vol.181 , pp. 3126-3136
    • Palazzo, M.1    Gariboldi, S.2    Zanobbio, L.3    Selleri, S.4    Dusio, G.F.5    Mauro, V.6
  • 161
    • 84866065884 scopus 로고    scopus 로고
    • Predominant role of active versus facilitative glucose transport for glucagon-like peptide-1 secretion
    • Parker, H.E., Adriaenssens, A., Rogers, G., Richards, P., Koepsell, H., Reimann, F., Gribble, F.M., Predominant role of active versus facilitative glucose transport for glucagon-like peptide-1 secretion. Diabetologia 55 (2012), 2445–2455.
    • (2012) Diabetologia , vol.55 , pp. 2445-2455
    • Parker, H.E.1    Adriaenssens, A.2    Rogers, G.3    Richards, P.4    Koepsell, H.5    Reimann, F.6    Gribble, F.M.7
  • 162
    • 58149464981 scopus 로고    scopus 로고
    • Nutrient-dependent secretion of glucose-dependent insulinotropic polypeptide from primary murine K cells
    • Parker, H.E., Habib, A.M., Rogers, G.J., Gribble, F.M., Reimann, F., Nutrient-dependent secretion of glucose-dependent insulinotropic polypeptide from primary murine K cells. Diabetologia 52 (2009), 289–298.
    • (2009) Diabetologia , vol.52 , pp. 289-298
    • Parker, H.E.1    Habib, A.M.2    Rogers, G.J.3    Gribble, F.M.4    Reimann, F.5
  • 163
    • 84899105421 scopus 로고    scopus 로고
    • Sodium-glucose cotransporter 2 inhibition and glycemic control in type 1 diabetes: Results of an 8-week open-label proof-of-concept trial
    • Perkins, B.A., Cherney, D.Z., Partridge, H., Soleymanlou, N., Tschirhart, H., Zinman, B., et al. Sodium-glucose cotransporter 2 inhibition and glycemic control in type 1 diabetes: Results of an 8-week open-label proof-of-concept trial. Diabetes Care 37 (2014), 1480–1483.
    • (2014) Diabetes Care , vol.37 , pp. 1480-1483
    • Perkins, B.A.1    Cherney, D.Z.2    Partridge, H.3    Soleymanlou, N.4    Tschirhart, H.5    Zinman, B.6
  • 164
    • 84962339296 scopus 로고    scopus 로고
    • Euglycemic diabetic ketoacidosis: a potential complication of treatment with sodium-glucose cotransporter 2 inhibition
    • Peters, A.L., Buschur, E.O., Buse, J.B., Cohan, P., Diner, J.C., Hirsch, I.B., Euglycemic diabetic ketoacidosis: a potential complication of treatment with sodium-glucose cotransporter 2 inhibition. Diabetes Care 38 (2015), 1687–1693.
    • (2015) Diabetes Care , vol.38 , pp. 1687-1693
    • Peters, A.L.1    Buschur, E.O.2    Buse, J.B.3    Cohan, P.4    Diner, J.C.5    Hirsch, I.B.6
  • 165
    • 0029839897 scopus 로고    scopus 로고
    • The epidermal growth factor receptor (EGF-R) is present on the basolateral, but not the apical, surface of enterocytes in the human gastrointestinal tract
    • Playford, R.J., Hanby, A.M., Gschmeissner, S., Peiffer, L.P., Wright, N.A., McGarrity, T., The epidermal growth factor receptor (EGF-R) is present on the basolateral, but not the apical, surface of enterocytes in the human gastrointestinal tract. Gut 39 (1996), 262–266.
    • (1996) Gut , vol.39 , pp. 262-266
    • Playford, R.J.1    Hanby, A.M.2    Gschmeissner, S.3    Peiffer, L.P.4    Wright, N.A.5    McGarrity, T.6
  • 166
    • 84877865378 scopus 로고    scopus 로고
    • Canagliflozin lowers postprandial glucose and insulin by delaying intestinal glucose absorption in addition to increasing urinary glucose excretion: Results of a randomized, placebo-controlled study
    • Polidori, D., Sha, S., Mudaliar, S., Ciaraldi, T.P., Ghosh, A., Vaccaro, N., et al. Canagliflozin lowers postprandial glucose and insulin by delaying intestinal glucose absorption in addition to increasing urinary glucose excretion: Results of a randomized, placebo-controlled study. Diabetes Care 36 (2013), 2154–2161.
    • (2013) Diabetes Care , vol.36 , pp. 2154-2161
    • Polidori, D.1    Sha, S.2    Mudaliar, S.3    Ciaraldi, T.P.4    Ghosh, A.5    Vaccaro, N.6
  • 168
    • 84900458799 scopus 로고    scopus 로고
    • Ipragliflozin: First global approval
    • Poole, R.M., Dungo, R.T., Ipragliflozin: First global approval. Drugs 74 (2014), 611–617.
    • (2014) Drugs , vol.74 , pp. 611-617
    • Poole, R.M.1    Dungo, R.T.2
  • 170
    • 84876519168 scopus 로고    scopus 로고
    • LX4211 increases serum glucagon-like peptide 1 and peptide YY levels by reducing sodium/glucose cotransporter 1 (SGLT1)-mediated absorption of intestinal glucose
    • Powell, D.R., Smith, M., Greer, J., Harris, A., Zhao, S., DaCosta, C., et al. LX4211 increases serum glucagon-like peptide 1 and peptide YY levels by reducing sodium/glucose cotransporter 1 (SGLT1)-mediated absorption of intestinal glucose. J Pharmacol Exp Ther 345 (2013), 250–259.
    • (2013) J Pharmacol Exp Ther , vol.345 , pp. 250-259
    • Powell, D.R.1    Smith, M.2    Greer, J.3    Harris, A.4    Zhao, S.5    DaCosta, C.6
  • 171
    • 84947786115 scopus 로고    scopus 로고
    • Treatment with the SGLT2 inhibitor luseogliflozin improves nonalcoholic steatohepatitis in a rodent model with diabetes mellitus
    • Qiang, S., Nakatsu, Y., Seno, Y., Fujishiro, M., Sakoda, H., Kushiyama, A., et al. Treatment with the SGLT2 inhibitor luseogliflozin improves nonalcoholic steatohepatitis in a rodent model with diabetes mellitus. Diabetol Metab Syndr, 7, 2015, 104.
    • (2015) Diabetol Metab Syndr , vol.7 , pp. 104
    • Qiang, S.1    Nakatsu, Y.2    Seno, Y.3    Fujishiro, M.4    Sakoda, H.5    Kushiyama, A.6
  • 172
    • 0037739964 scopus 로고    scopus 로고
    • Post-challenge hyperglycaemia is associated with premature death and macrovascular complications
    • Qiao, Q., Tuomilehto, J., Borch-Johnsen, K., Post-challenge hyperglycaemia is associated with premature death and macrovascular complications. Diabetologia 46:Suppl 1 (2003), M17–M21.
    • (2003) Diabetologia , vol.46 , pp. M17-M21
    • Qiao, Q.1    Tuomilehto, J.2    Borch-Johnsen, K.3
  • 173
    • 84946491938 scopus 로고    scopus 로고
    • Role of the renal sympathetic nerve in renal glucose metabolism during the development of type 2 diabetes in rats
    • Rafiq, K., Fujisawa, Y., Sherajee, S.J., Rahman, A., Sufiun, A., Kobori, H., et al. Role of the renal sympathetic nerve in renal glucose metabolism during the development of type 2 diabetes in rats. Diabetologia 58 (2015), 2885–2898.
    • (2015) Diabetologia , vol.58 , pp. 2885-2898
    • Rafiq, K.1    Fujisawa, Y.2    Sherajee, S.J.3    Rahman, A.4    Sufiun, A.5    Kobori, H.6
  • 174
    • 33644688031 scopus 로고    scopus 로고
    • Glucose transporters in human renal proximal tubular cells isolated from the urine of patients with non-insulin-dependent diabetes
    • Rahmoune, H., Thompson, P.W., Ward, J.M., Smith, C.D., Hong, G., Brown, J., Glucose transporters in human renal proximal tubular cells isolated from the urine of patients with non-insulin-dependent diabetes. Diabetes 54 (2005), 3427–3434.
    • (2005) Diabetes , vol.54 , pp. 3427-3434
    • Rahmoune, H.1    Thompson, P.W.2    Ward, J.M.3    Smith, C.D.4    Hong, G.5    Brown, J.6
  • 175
    • 33947573919 scopus 로고    scopus 로고
    • Sensing of glucose in the gastrointestinal tract
    • Raybould, H.E., Sensing of glucose in the gastrointestinal tract. Auton Neurosci 133 (2007), 86–90.
    • (2007) Auton Neurosci , vol.133 , pp. 86-90
    • Raybould, H.E.1
  • 177
    • 84882247018 scopus 로고    scopus 로고
    • EGFR-SGLT1 interaction does not respond to EGFR modulators, but inhibition of SGLT1 sensitizes prostate cancer cells to EGFR tyrosine kinase inhibitors
    • Ren, J., Bollu, L.R., Su, F., Gao, G., Xu, L., Huang, W.C., et al. EGFR-SGLT1 interaction does not respond to EGFR modulators, but inhibition of SGLT1 sensitizes prostate cancer cells to EGFR tyrosine kinase inhibitors. Prostate 73 (2013), 1453–1461.
    • (2013) Prostate , vol.73 , pp. 1453-1461
    • Ren, J.1    Bollu, L.R.2    Su, F.3    Gao, G.4    Xu, L.5    Huang, W.C.6
  • 179
    • 84908332537 scopus 로고    scopus 로고
    • Comparison of empagliflozin and glimepiride as add-on to metformin in patients with type 2 diabetes: A 104-week randomised, active-controlled, double-blind, phase 3 trial
    • Ridderstrale, M., Andersen, K.R., Zeller, C., Kim, G., Woerle, H.J., Broedl, U.C., Comparison of empagliflozin and glimepiride as add-on to metformin in patients with type 2 diabetes: A 104-week randomised, active-controlled, double-blind, phase 3 trial. Lancet Diabetes Endocrinol 2 (2014), 691–700.
    • (2014) Lancet Diabetes Endocrinol , vol.2 , pp. 691-700
    • Ridderstrale, M.1    Andersen, K.R.2    Zeller, C.3    Kim, G.4    Woerle, H.J.5    Broedl, U.C.6
  • 180
    • 84892576563 scopus 로고    scopus 로고
    • Increase in SGLT1-mediated transport explains renal glucose reabsorption during genetic and pharmacological SGLT2 inhibition in euglycemia
    • Rieg, T., Masuda, T., Gerasimova, M., Mayoux, E., Platt, K., Powell, D.R., et al. Increase in SGLT1-mediated transport explains renal glucose reabsorption during genetic and pharmacological SGLT2 inhibition in euglycemia. Am J Physiol Renal Physiol 306 (2014), F188–F193.
    • (2014) Am J Physiol Renal Physiol , vol.306 , pp. F188-F193
    • Rieg, T.1    Masuda, T.2    Gerasimova, M.3    Mayoux, E.4    Platt, K.5    Powell, D.R.6
  • 181
    • 84901491136 scopus 로고    scopus 로고
    • Usefulness of F-18-fluorodeoxyglucose positron emission tomography to confirm suspected pancreatic cancer: a meta-analysis
    • Rijkers, A.P., Valkema, R., Duivenvoorden, H.J., van Eijck, C.H., Usefulness of F-18-fluorodeoxyglucose positron emission tomography to confirm suspected pancreatic cancer: a meta-analysis. Eur J Surg Oncol 40 (2014), 794–804.
    • (2014) Eur J Surg Oncol , vol.40 , pp. 794-804
    • Rijkers, A.P.1    Valkema, R.2    Duivenvoorden, H.J.3    van Eijck, C.H.4
  • 182
    • 84962069581 scopus 로고    scopus 로고
    • Initial combination therapy with canagliflozin plus metformin versus each component as monotherapy for drug-naive type 2 diabetes
    • Rosenstock, J., Chuck, L., Gonzalez-Ortiz, M., Merton, K., Craig, J., Capuano, G., Qiu, R., Initial combination therapy with canagliflozin plus metformin versus each component as monotherapy for drug-naive type 2 diabetes. Diabetes Care 39 (2016), 353–362.
    • (2016) Diabetes Care , vol.39 , pp. 353-362
    • Rosenstock, J.1    Chuck, L.2    Gonzalez-Ortiz, M.3    Merton, K.4    Craig, J.5    Capuano, G.6    Qiu, R.7
  • 183
    • 84928201032 scopus 로고    scopus 로고
    • Dual add-on therapy in type 2 diabetes poorly controlled with metformin monotherapy: A randomized double-blind trial of saxagliptin plus dapagliflozin addition versus single addition of saxagliptin or dapagliflozin to metformin
    • Rosenstock, J., Hansen, L., Zee, P., Li, Y., Cook, W., Hirshberg, B., Iqbal, N., Dual add-on therapy in type 2 diabetes poorly controlled with metformin monotherapy: A randomized double-blind trial of saxagliptin plus dapagliflozin addition versus single addition of saxagliptin or dapagliflozin to metformin. Diabetes Care 38 (2015), 376–383.
    • (2015) Diabetes Care , vol.38 , pp. 376-383
    • Rosenstock, J.1    Hansen, L.2    Zee, P.3    Li, Y.4    Cook, W.5    Hirshberg, B.6    Iqbal, N.7
  • 184
    • 84903511385 scopus 로고    scopus 로고
    • Improved glucose control with weight loss, lower insulin doses, and no increased hypoglycemia with empagliflozin added to titrated multiple daily injections of insulin in obese inadequately controlled type 2 diabetes
    • Rosenstock, J., Jelaska, A., Frappin, G., Salsali, A., Kim, G., Woerle, H.J., Broedl, U.C., Improved glucose control with weight loss, lower insulin doses, and no increased hypoglycemia with empagliflozin added to titrated multiple daily injections of insulin in obese inadequately controlled type 2 diabetes. Diabetes Care 37 (2014), 1815–1823.
    • (2014) Diabetes Care , vol.37 , pp. 1815-1823
    • Rosenstock, J.1    Jelaska, A.2    Frappin, G.3    Salsali, A.4    Kim, G.5    Woerle, H.J.6    Broedl, U.C.7
  • 186
    • 0023275573 scopus 로고
    • Correction of hyperglycemia with phlorizin normalizes tissue sensitivity to insulin in diabetic rats
    • Rossetti, L., Smith, D., Shulman, G.I., Papachristou, D., DeFronzo, R.A., Correction of hyperglycemia with phlorizin normalizes tissue sensitivity to insulin in diabetic rats. J Clin Invest 79 (1987), 1510–1515.
    • (1987) J Clin Invest , vol.79 , pp. 1510-1515
    • Rossetti, L.1    Smith, D.2    Shulman, G.I.3    Papachristou, D.4    DeFronzo, R.A.5
  • 189
    • 84963966467 scopus 로고    scopus 로고
    • Clinical implications of cardiovascular outcome trials in type 2 diabetes: From DCCT to EMPA-REG
    • Ryden, L., Shahim, B., Mellbin, L., Clinical implications of cardiovascular outcome trials in type 2 diabetes: From DCCT to EMPA-REG. Clin Ther 38 (2016), 1279–1287, 10.1016/j.clinthera.2016.03.035.
    • (2016) Clin Ther , vol.38 , pp. 1279-1287
    • Ryden, L.1    Shahim, B.2    Mellbin, L.3
  • 190
    • 32644481587 scopus 로고    scopus 로고
    • High glucose transactivates the EGF receptor and up-regulates serum glucocorticoid kinase in the proximal tubule
    • Saad, S., Stevens, V.A., Wassef, L., Poronnik, P., Kelly, D.J., Gilbert, R.E., Pollock, C.A., High glucose transactivates the EGF receptor and up-regulates serum glucocorticoid kinase in the proximal tubule. Kidney Int 68 (2005), 985–997.
    • (2005) Kidney Int , vol.68 , pp. 985-997
    • Saad, S.1    Stevens, V.A.2    Wassef, L.3    Poronnik, P.4    Kelly, D.J.5    Gilbert, R.E.6    Pollock, C.A.7
  • 191
    • 48449097409 scopus 로고    scopus 로고
    • The locus for hypoglycemic detection shifts with the rate of fall in glycemia: The role of portal-superior mesenteric vein glucose sensing
    • Saberi, M., Bohland, M., Donovan, C.M., The locus for hypoglycemic detection shifts with the rate of fall in glycemia: The role of portal-superior mesenteric vein glucose sensing. Diabetes 57 (2008), 1380–1386.
    • (2008) Diabetes , vol.57 , pp. 1380-1386
    • Saberi, M.1    Bohland, M.2    Donovan, C.M.3
  • 193
    • 0025268248 scopus 로고
    • Ventromedial hypothalamic lesions attenuate responses of sympathetic nerves to carotid arterial infusions of glucose and insulin
    • Sakaguchi, T., Bray, G.A., Ventromedial hypothalamic lesions attenuate responses of sympathetic nerves to carotid arterial infusions of glucose and insulin. Int J Obes 14 (1990), 127–133.
    • (1990) Int J Obes , vol.14 , pp. 127-133
    • Sakaguchi, T.1    Bray, G.A.2
  • 194
    • 84961801299 scopus 로고    scopus 로고
    • Efficacy and safety of the SGLT2 inhibitor luseogliflozin in Japanese patients with type 2 diabetes mellitus stratified according to baseline body mass index: pooled analysis of data from 52-week phase III trials
    • Sakai, S., Kaku, K., Seino, Y., Inagaki, N., Haneda, M., Sasaki, T., et al. Efficacy and safety of the SGLT2 inhibitor luseogliflozin in Japanese patients with type 2 diabetes mellitus stratified according to baseline body mass index: pooled analysis of data from 52-week phase III trials. Clin Ther 38 (2016), 843–862.
    • (2016) Clin Ther , vol.38 , pp. 843-862
    • Sakai, S.1    Kaku, K.2    Seino, Y.3    Inagaki, N.4    Haneda, M.5    Sasaki, T.6
  • 195
    • 75749094398 scopus 로고    scopus 로고
    • Familial renal glucosuria and SGLT2: From a mendelian trait to a therapeutic target
    • Santer, R., Calado, J., Familial renal glucosuria and SGLT2: From a mendelian trait to a therapeutic target. Clin J Am Soc Nephrol 5 (2010), 133–141.
    • (2010) Clin J Am Soc Nephrol , vol.5 , pp. 133-141
    • Santer, R.1    Calado, J.2
  • 197
    • 84964507777 scopus 로고    scopus 로고
    • SGLT2 inhibition and cardiovascular events: Why did EMPA-REG outcomes surprise and what were the likely mechanisms?
    • Sattar, N., McLaren, J., Kristensen, S.L., Preiss, D., McMurray, J.J., SGLT2 inhibition and cardiovascular events: Why did EMPA-REG outcomes surprise and what were the likely mechanisms?. Diabetologia 59 (2016), 1333–1339.
    • (2016) Diabetologia , vol.59 , pp. 1333-1339
    • Sattar, N.1    McLaren, J.2    Kristensen, S.L.3    Preiss, D.4    McMurray, J.J.5
  • 199
    • 84923791994 scopus 로고    scopus 로고
    • Pharmacodynamics, efficacy and safety of sodium-glucose co-transporter type 2 (SGLT2) inhibitors for the treatment of type 2 diabetes mellitus
    • Scheen, A.J., Pharmacodynamics, efficacy and safety of sodium-glucose co-transporter type 2 (SGLT2) inhibitors for the treatment of type 2 diabetes mellitus. Drugs 75 (2015), 33–59.
    • (2015) Drugs , vol.75 , pp. 33-59
    • Scheen, A.J.1
  • 200
    • 84933676007 scopus 로고    scopus 로고
    • Pharmacokinetics, pharmacodynamics and clinical use of SGLT2 inhibitors in patients with type 2 diabetes mellitus and chronic kidney disease
    • Scheen, A.J., Pharmacokinetics, pharmacodynamics and clinical use of SGLT2 inhibitors in patients with type 2 diabetes mellitus and chronic kidney disease. Clin Pharmacokinet 54 (2015), 691–708.
    • (2015) Clin Pharmacokinet , vol.54 , pp. 691-708
    • Scheen, A.J.1
  • 201
    • 84891784200 scopus 로고    scopus 로고
    • Canagliflozin compared with sitagliptin for patients with type 2 diabetes who do not have adequate glycemic control with metformin plus sulfonylurea: a 52-week randomized trial
    • Schernthaner, G., Gross, J.L., Rosenstock, J., Guarisco, M., Fu, M., Yee, J., et al. Canagliflozin compared with sitagliptin for patients with type 2 diabetes who do not have adequate glycemic control with metformin plus sulfonylurea: a 52-week randomized trial. Diabetes Care 36 (2013), 2508–2515.
    • (2013) Diabetes Care , vol.36 , pp. 2508-2515
    • Schernthaner, G.1    Gross, J.L.2    Rosenstock, J.3    Guarisco, M.4    Fu, M.5    Yee, J.6
  • 202
    • 0032948191 scopus 로고    scopus 로고
    • 2, in glucose absorption via the sodium dependent glucose transporter-1 in rat intestine
    • 2, in glucose absorption via the sodium dependent glucose transporter-1 in rat intestine. Gut 44 (1999), 490–496.
    • (1999) Gut , vol.44 , pp. 490-496
    • Scholtka, B.1    Stümpel, F.2    Jungermann, K.3
  • 203
    • 84861127361 scopus 로고    scopus 로고
    • Role of gut nutrient sensing in stimulating appetite and conditioning food preferences
    • Sclafani, A., Ackroff, K., Role of gut nutrient sensing in stimulating appetite and conditioning food preferences. Am J Physiol Regul Integr Comp Physiol 302 (2012), R1119–R1133.
    • (2012) Am J Physiol Regul Integr Comp Physiol , vol.302 , pp. R1119-R1133
    • Sclafani, A.1    Ackroff, K.2
  • 204
    • 84984607321 scopus 로고    scopus 로고
    • SGLT1 sugar transporter/sensor is required for post-oral glucose appetition
    • Sclafani, A., Koepsell, H., Ackroff, K., SGLT1 sugar transporter/sensor is required for post-oral glucose appetition. Am J Physiol Regul Integr Comp Physiol 310 (2016), R631–R639.
    • (2016) Am J Physiol Regul Integr Comp Physiol , vol.310 , pp. R631-R639
    • Sclafani, A.1    Koepsell, H.2    Ackroff, K.3
  • 205
    • 79956331954 scopus 로고    scopus 로고
    • Canagliflozin, a novel inhibitor of sodium glucose co-transporter 2, dose dependently reduces calculated renal threshold for glucose excretion and increases urinary glucose excretion in healthy subjects
    • Sha, S., Devineni, D., Ghosh, A., Polidori, D., Chien, S., Wexler, D., et al. Canagliflozin, a novel inhibitor of sodium glucose co-transporter 2, dose dependently reduces calculated renal threshold for glucose excretion and increases urinary glucose excretion in healthy subjects. Diabetes Obes Metab 13 (2011), 669–672.
    • (2011) Diabetes Obes Metab , vol.13 , pp. 669-672
    • Sha, S.1    Devineni, D.2    Ghosh, A.3    Polidori, D.4    Chien, S.5    Wexler, D.6
  • 207
    • 84864118760 scopus 로고    scopus 로고
    • KGA-2727, a novel selective inhibitor of a high-affinity sodium glucose cotransporter (SGLT1), exhibits antidiabetic efficacy in rodent models
    • Shibazaki, T., Tomae, M., Ishikawa-Takemura, Y., Fushimi, N., Itoh, F., Yamada, M., Isaji, M., KGA-2727, a novel selective inhibitor of a high-affinity sodium glucose cotransporter (SGLT1), exhibits antidiabetic efficacy in rodent models. J Pharmacol Exp Ther 342 (2012), 288–296.
    • (2012) J Pharmacol Exp Ther , vol.342 , pp. 288-296
    • Shibazaki, T.1    Tomae, M.2    Ishikawa-Takemura, Y.3    Fushimi, N.4    Itoh, F.5    Yamada, M.6    Isaji, M.7
  • 208
    • 24344503323 scopus 로고    scopus 로고
    • Post-prandial hyperglycemia is an important predictor of the incidence of diabetic microangiopathy in Japanese type 2 diabetic patients
    • Shiraiwa, T., Kaneto, H., Miyatsuka, T., Kato, K., Yamamoto, K., Kawashima, A., et al. Post-prandial hyperglycemia is an important predictor of the incidence of diabetic microangiopathy in Japanese type 2 diabetic patients. Biochem Biophys Res Commun 336 (2005), 339–345.
    • (2005) Biochem Biophys Res Commun , vol.336 , pp. 339-345
    • Shiraiwa, T.1    Kaneto, H.2    Miyatsuka, T.3    Kato, K.4    Yamamoto, K.5    Kawashima, A.6
  • 209
    • 84960433486 scopus 로고    scopus 로고
    • SGLT-2 receptor inhibitors for treating patients with type 2 diabetes mellitus: a systematic review and network meta-analysis
    • Shyangdan, D.S., Uthman, O.A., Waugh, N., SGLT-2 receptor inhibitors for treating patients with type 2 diabetes mellitus: a systematic review and network meta-analysis. BMJ Open, 6, 2016, e009417.
    • (2016) BMJ Open , vol.6
    • Shyangdan, D.S.1    Uthman, O.A.2    Waugh, N.3
  • 210
    • 84971635917 scopus 로고    scopus 로고
    • Sodium glucose cotransporter SGLT1 as a therapeutic target in diabetes mellitus
    • Song, P., Onishi, A., Koepsell, H., Vallon, V., Sodium glucose cotransporter SGLT1 as a therapeutic target in diabetes mellitus. Expert Opin Ther Targets, 2016, 10.1517/14728222.2016.1168808.
    • (2016) Expert Opin Ther Targets
    • Song, P.1    Onishi, A.2    Koepsell, H.3    Vallon, V.4
  • 211
    • 0031791027 scopus 로고    scopus 로고
    • Enteric glucagon 37 rather than pancreatic glucagon 29 stimulates glucose absorption in rat intestine
    • Stümpel, F., Scholtka, B., Hunger, A., Jungermann, K., Enteric glucagon 37 rather than pancreatic glucagon 29 stimulates glucose absorption in rat intestine. Gastroenterology 115 (1998), 1163–1171.
    • (1998) Gastroenterology , vol.115 , pp. 1163-1171
    • Stümpel, F.1    Scholtka, B.2    Hunger, A.3    Jungermann, K.4
  • 212
    • 0034519317 scopus 로고    scopus 로고
    • Stimulation by portal insulin of intestinal glucose absorption via hepatoenteral nerves and prostaglandin E2 in the isolated, jointly perfused small intestine and liver of the rat
    • Stümpel, F., Scholtka, B., Jungermann, K., Stimulation by portal insulin of intestinal glucose absorption via hepatoenteral nerves and prostaglandin E2 in the isolated, jointly perfused small intestine and liver of the rat. Ann N Y Acad Sci 915 (2000), 111–116.
    • (2000) Ann N Y Acad Sci , vol.915 , pp. 111-116
    • Stümpel, F.1    Scholtka, B.2    Jungermann, K.3
  • 213
    • 84861536065 scopus 로고    scopus 로고
    • Tofogliflozin, a potent and highly specific sodium/glucose cotransporter 2 inhibitor, improves glycemic control in diabetic rats and mice
    • Suzuki, M., Honda, K., Fukazawa, M., Ozawa, K., Hagita, H., Kawai, T., et al. Tofogliflozin, a potent and highly specific sodium/glucose cotransporter 2 inhibitor, improves glycemic control in diabetic rats and mice. J Pharmacol Exp Ther 341 (2012), 692–701.
    • (2012) J Pharmacol Exp Ther , vol.341 , pp. 692-701
    • Suzuki, M.1    Honda, K.2    Fukazawa, M.3    Ozawa, K.4    Hagita, H.5    Kawai, T.6
  • 214
    • 57949111356 scopus 로고    scopus 로고
    • Enhanced expressions of sodium-glucose cotransporters in the kidneys of diabetic Zucker rats
    • Tabatabai, N.M., Sharma, M., Blumenthal, S.S., Petering, D.H., Enhanced expressions of sodium-glucose cotransporters in the kidneys of diabetic Zucker rats. Diabetes Res Clin Pract 83 (2009), e27–e30.
    • (2009) Diabetes Res Clin Pract , vol.83 , pp. e27-e30
    • Tabatabai, N.M.1    Sharma, M.2    Blumenthal, S.S.3    Petering, D.H.4
  • 215
    • 84866541730 scopus 로고    scopus 로고
    • Antidiabetic effects of SGLT2-selective inhibitor ipragliflozin in streptozotocin-nicotinamide-induced mildly diabetic mice
    • Tahara, A., Kurosaki, E., Yokono, M., Yamajuku, D., Kihara, R., Hayashizaki, Y., et al. Antidiabetic effects of SGLT2-selective inhibitor ipragliflozin in streptozotocin-nicotinamide-induced mildly diabetic mice. J Pharmacol Sci 120 (2012), 36–44.
    • (2012) J Pharmacol Sci , vol.120 , pp. 36-44
    • Tahara, A.1    Kurosaki, E.2    Yokono, M.3    Yamajuku, D.4    Kihara, R.5    Hayashizaki, Y.6
  • 216
    • 84885476895 scopus 로고    scopus 로고
    • Effects of SGLT2 selective inhibitor ipragliflozin on hyperglycemia, hyperlipidemia, hepatic steatosis, oxidative stress, inflammation, and obesity in type 2 diabetic mice
    • Tahara, A., Kurosaki, E., Yokono, M., Yamajuku, D., Kihara, R., Hayashizaki, Y., et al. Effects of SGLT2 selective inhibitor ipragliflozin on hyperglycemia, hyperlipidemia, hepatic steatosis, oxidative stress, inflammation, and obesity in type 2 diabetic mice. Eur J Pharmacol 715 (2013), 246–255.
    • (2013) Eur J Pharmacol , vol.715 , pp. 246-255
    • Tahara, A.1    Kurosaki, E.2    Yokono, M.3    Yamajuku, D.4    Kihara, R.5    Hayashizaki, Y.6
  • 217
    • 84959890006 scopus 로고    scopus 로고
    • Characterization and comparison of sodium-glucose cotransporter 2 inhibitors in pharmacokinetics, pharmacodynamics, and pharmacologic effects
    • Tahara, A., Takasu, T., Yokono, M., Imamura, M., Kurosaki, E., Characterization and comparison of sodium-glucose cotransporter 2 inhibitors in pharmacokinetics, pharmacodynamics, and pharmacologic effects. J Pharmacol Sci 130 (2016), 159–169.
    • (2016) J Pharmacol Sci , vol.130 , pp. 159-169
    • Tahara, A.1    Takasu, T.2    Yokono, M.3    Imamura, M.4    Kurosaki, E.5
  • 218
    • 84957586606 scopus 로고    scopus 로고
    • Effect of ipragliflozin, an SGLT2 inhibitor, on progression of diabetic microvascular complications in spontaneously diabetic Torii fatty rats
    • Takakura, S., Toyoshi, T., Hayashizaki, Y., Takasu, T., Effect of ipragliflozin, an SGLT2 inhibitor, on progression of diabetic microvascular complications in spontaneously diabetic Torii fatty rats. Life Sci 147 (2016), 125–131.
    • (2016) Life Sci , vol.147 , pp. 125-131
    • Takakura, S.1    Toyoshi, T.2    Hayashizaki, Y.3    Takasu, T.4
  • 220
    • 84939142605 scopus 로고    scopus 로고
    • SGLT2 inhibitors may predispose to ketoacidosis
    • Taylor, S.I., Blau, J.E., Rother, K.I., SGLT2 inhibitors may predispose to ketoacidosis. J Clin Endocrinol Metab 100 (2015), 2849–2852.
    • (2015) J Clin Endocrinol Metab , vol.100 , pp. 2849-2852
    • Taylor, S.I.1    Blau, J.E.2    Rother, K.I.3
  • 222
    • 84903528312 scopus 로고    scopus 로고
    • Long-term treatment with the sodium glucose cotransporter 2 inhibitor, dapagliflozin, ameliorates glucose homeostasis and diabetic nephropathy in db/db mice
    • Terami, N., Ogawa, D., Tachibana, H., Hatanaka, T., Wada, J., Nakatsuka, A., et al. Long-term treatment with the sodium glucose cotransporter 2 inhibitor, dapagliflozin, ameliorates glucose homeostasis and diabetic nephropathy in db/db mice. PLoS One, 9, 2014, e100777.
    • (2014) PLoS One , vol.9
    • Terami, N.1    Ogawa, D.2    Tachibana, H.3    Hatanaka, T.4    Wada, J.5    Nakatsuka, A.6
  • 223
    • 0030018911 scopus 로고    scopus 로고
    • +-glucose cotransporter inhibitors as antidiabetics. I. Synthesis and pharmacological properties of 4′-dehydroxyphlorizin derivatives based on a new concept
    • +-glucose cotransporter inhibitors as antidiabetics. I. Synthesis and pharmacological properties of 4′-dehydroxyphlorizin derivatives based on a new concept. Chem Pharm Bull 44 (1996), 1174–1180.
    • (1996) Chem Pharm Bull , vol.44 , pp. 1174-1180
    • Tsujihara, K.1    Hongu, M.2    Saito, K.3    Inamasu, M.4    Arakawa, K.5    Oku, A.6    Maisumoto, M.7
  • 225
    • 84855459920 scopus 로고    scopus 로고
    • Glucagonocentric restructuring of diabetes: A pathophysiologic and therapeutic makeover
    • Unger, R.H., Cherrington, A.D., Glucagonocentric restructuring of diabetes: A pathophysiologic and therapeutic makeover. J Clin Invest 122 (2012), 4–12.
    • (2012) J Clin Invest , vol.122 , pp. 4-12
    • Unger, R.H.1    Cherrington, A.D.2
  • 226
    • 84906924894 scopus 로고    scopus 로고
    • Safety and tolerability of canagliflozin in patients with type 2 diabetes mellitus: pooled analysis of phase 3 study results
    • Usiskin, K., Kline, I., Fung, A., Mayer, C., Meininger, G., Safety and tolerability of canagliflozin in patients with type 2 diabetes mellitus: pooled analysis of phase 3 study results. Postgrad Med 126 (2014), 16–34.
    • (2014) Postgrad Med , vol.126 , pp. 16-34
    • Usiskin, K.1    Kline, I.2    Fung, A.3    Mayer, C.4    Meininger, G.5
  • 227
    • 79955771730 scopus 로고    scopus 로고
    • The proximal tubule in the pathophysiology of the diabetic kidney
    • Vallon, V., The proximal tubule in the pathophysiology of the diabetic kidney. Am J Physiol Regul Integr Comp Physiol 300 (2011), R1009–R1022.
    • (2011) Am J Physiol Regul Integr Comp Physiol , vol.300 , pp. R1009-R1022
    • Vallon, V.1
  • 228
    • 84921374064 scopus 로고    scopus 로고
    • The mechanisms and therapeutic potential of SGLT2 inhibitors in diabetes mellitus
    • Vallon, V., The mechanisms and therapeutic potential of SGLT2 inhibitors in diabetes mellitus. Annu Rev Med 66 (2015), 255–270.
    • (2015) Annu Rev Med , vol.66 , pp. 255-270
    • Vallon, V.1
  • 229
    • 84892588641 scopus 로고    scopus 로고
    • SGLT2 inhibitor empagliflozin reduces renal growth and albuminuria in proportion to hyperglycemia and prevents glomerular hyperfiltration in diabetic Akita mice
    • Vallon, V., Gerasimova, M., Rose, M.A., Masuda, T., Satriano, J., Mayoux, E., et al. SGLT2 inhibitor empagliflozin reduces renal growth and albuminuria in proportion to hyperglycemia and prevents glomerular hyperfiltration in diabetic Akita mice. Am J Physiol Renal Physiol 306 (2014), F194–F204.
    • (2014) Am J Physiol Renal Physiol , vol.306 , pp. F194-F204
    • Vallon, V.1    Gerasimova, M.2    Rose, M.A.3    Masuda, T.4    Satriano, J.5    Mayoux, E.6
  • 231
    • 84872400230 scopus 로고    scopus 로고
    • Knockout of Na-glucose transporter SGLT2 attenuates hyperglycemia and glomerular hyperfiltration but not kidney growth or injury in diabetes mellitus
    • Vallon, V., Rose, M., Gerasimova, M., Satriano, J., Platt, K.A., Koepsell, H., et al. Knockout of Na-glucose transporter SGLT2 attenuates hyperglycemia and glomerular hyperfiltration but not kidney growth or injury in diabetes mellitus. Am J Physiol Renal Physiol 304 (2012), F156–F167.
    • (2012) Am J Physiol Renal Physiol , vol.304 , pp. F156-F167
    • Vallon, V.1    Rose, M.2    Gerasimova, M.3    Satriano, J.4    Platt, K.A.5    Koepsell, H.6
  • 232
    • 84882251091 scopus 로고    scopus 로고
    • Sodium-glucose cotransporter 2 inhibitors for type 2 diabetes: a systematic review and meta-analysis
    • Vasilakou, D., Karagiannis, T., Athanasiadou, E., Mainou, M., Liakos, A., Bekiari, E., et al. Sodium-glucose cotransporter 2 inhibitors for type 2 diabetes: a systematic review and meta-analysis. Ann Intern Med 159 (2013), 262–274.
    • (2013) Ann Intern Med , vol.159 , pp. 262-274
    • Vasilakou, D.1    Karagiannis, T.2    Athanasiadou, E.3    Mainou, M.4    Liakos, A.5    Bekiari, E.6
  • 233
    • 0033052459 scopus 로고    scopus 로고
    • +-glucose transporter expressed in COS-7 cells
    • +-glucose transporter expressed in COS-7 cells. Am J Physiol Cell Physiol 276 (1999), C1053–C1060.
    • (1999) Am J Physiol Cell Physiol , vol.276 , pp. C1053-C1060
    • Vayro, S.1    Silverman, M.2
  • 234
    • 0034786793 scopus 로고    scopus 로고
    • +/glucose cotransporter SGLT1 gene. Role of HNF-1 in glucose activation of promoter function
    • +/glucose cotransporter SGLT1 gene. Role of HNF-1 in glucose activation of promoter function. Eur J Biochem 268 (2001), 5460–5470.
    • (2001) Eur J Biochem , vol.268 , pp. 5460-5470
    • Vayro, S.1    Wood, I.S.2    Dyer, J.3    Shirazi-Beechey, S.P.4
  • 236
    • 0035879385 scopus 로고    scopus 로고
    • Changes in sodium or glucose filtration rate modulate expression of glucose transporters in renal proximal tubular cells of rat
    • Vestri, S., Okamoto, M.M., de Freitas, H.S., Aparecida dos Santos, R., Nunes, M.T., Morimatsu, M., et al. Changes in sodium or glucose filtration rate modulate expression of glucose transporters in renal proximal tubular cells of rat. J Membr Biol 182 (2001), 105–112.
    • (2001) J Membr Biol , vol.182 , pp. 105-112
    • Vestri, S.1    Okamoto, M.M.2    de Freitas, H.S.3    Aparecida dos Santos, R.4    Nunes, M.T.5    Morimatsu, M.6
  • 239
    • 84958158188 scopus 로고    scopus 로고
    • Phosphorylation of RS1 (RSC1A1) steers inhibition of different exocytotic pathways for glucose transporter SGLT1 and nucleoside transporter CNT1 and a RS1 derived peptide inhibits glucose absorption
    • Veyhl-Wichmann, M., Friedrich, A., Vernaleken, A., Singh, S., Kipp, H., Gorboulev, V., et al. Phosphorylation of RS1 (RSC1A1) steers inhibition of different exocytotic pathways for glucose transporter SGLT1 and nucleoside transporter CNT1 and a RS1 derived peptide inhibits glucose absorption. Mol Pharmacol 89 (2016), 118–132.
    • (2016) Mol Pharmacol , vol.89 , pp. 118-132
    • Veyhl-Wichmann, M.1    Friedrich, A.2    Vernaleken, A.3    Singh, S.4    Kipp, H.5    Gorboulev, V.6
  • 240
    • 0001095690 scopus 로고    scopus 로고
    • Reduced postprandial concentrations of intact biologically active glucagon-like peptide 1 in type 2 diabetic patients
    • Vilsboll, T., Krarup, T., Deacon, C.F., Madsbad, S., Holst, J.J., Reduced postprandial concentrations of intact biologically active glucagon-like peptide 1 in type 2 diabetic patients. Diabetes 50 (2001), 609–613.
    • (2001) Diabetes , vol.50 , pp. 609-613
    • Vilsboll, T.1    Krarup, T.2    Deacon, C.F.3    Madsbad, S.4    Holst, J.J.5
  • 241
    • 79959320677 scopus 로고    scopus 로고
    • Intestinal glucose-induced calcium-calmodulin kinase signaling in the gut-brain axis in awake rats
    • Vincent, K.M., Sharp, J.W., Raybould, H.E., Intestinal glucose-induced calcium-calmodulin kinase signaling in the gut-brain axis in awake rats. Neurogastroenterol Motil 23 (2011), e282–e293.
    • (2011) Neurogastroenterol Motil , vol.23 , pp. e282-e293
    • Vincent, K.M.1    Sharp, J.W.2    Raybould, H.E.3
  • 242
    • 77952803960 scopus 로고    scopus 로고
    • Glucose-transporter-mediated positive inotropic effects in human myocardium of diabetic and nondiabetic patients
    • von Lewinski, D., Rainer, P.P., Gasser, R., Huber, M.S., Khafaga, M., Wilhelm, B., et al. Glucose-transporter-mediated positive inotropic effects in human myocardium of diabetic and nondiabetic patients. Metabolism 59 (2010), 1020–1028.
    • (2010) Metabolism , vol.59 , pp. 1020-1028
    • von Lewinski, D.1    Rainer, P.P.2    Gasser, R.3    Huber, M.S.4    Khafaga, M.5    Wilhelm, B.6
  • 244
    • 84943234625 scopus 로고    scopus 로고
    • +-D-glucose cotransporters SGLT1 and SGLT2 in human kidney and of SGLT1 in human small intestine, liver, lung, and heart
    • +-D-glucose cotransporters SGLT1 and SGLT2 in human kidney and of SGLT1 in human small intestine, liver, lung, and heart. Pflugers Arch 467 (2015), 1881–1898.
    • (2015) Pflugers Arch , vol.467 , pp. 1881-1898
    • Vrhovac, I.1    Balen, E.D.2    Klessen, D.3    Burger, C.4    Breljak, D.5    Kraus, O.6
  • 247
    • 84875150979 scopus 로고    scopus 로고
    • Differentiating sodium-glucose co-transporter-2 inhibitors in development for the treatment of type 2 diabetes mellitus
    • Washburn, W.N., Poucher, S.M., Differentiating sodium-glucose co-transporter-2 inhibitors in development for the treatment of type 2 diabetes mellitus. Expert Opin Investig Drugs 22 (2013), 463–486.
    • (2013) Expert Opin Investig Drugs , vol.22 , pp. 463-486
    • Washburn, W.N.1    Poucher, S.M.2
  • 248
    • 42949176742 scopus 로고    scopus 로고
    • Survival of cancer cells is maintained by EGFR independent of its kinase activity
    • Weihua, Z., Tsan, R., Huang, W.-C., Wu, Q., Chiu, C.-H., Fidler, I.J., Hung, M.-C., Survival of cancer cells is maintained by EGFR independent of its kinase activity. Cancer Cell 13 (2008), 385–393.
    • (2008) Cancer Cell , vol.13 , pp. 385-393
    • Weihua, Z.1    Tsan, R.2    Huang, W.-C.3    Wu, Q.4    Chiu, C.-H.5    Fidler, I.J.6    Hung, M.-C.7
  • 249
    • 84964010047 scopus 로고    scopus 로고
    • The kidney and type 2 diabetes mellitus: Therapeutic implications of SGLT2 inhibitors
    • Weir, M.R., The kidney and type 2 diabetes mellitus: Therapeutic implications of SGLT2 inhibitors. Postgrad Med 128 (2016), 290–298.
    • (2016) Postgrad Med , vol.128 , pp. 290-298
    • Weir, M.R.1
  • 250
    • 84858323889 scopus 로고    scopus 로고
    • Long-term efficacy of dapagliflozin in patients with type 2 diabetes mellitus receiving high doses of insulin: A randomized trial
    • Wilding, J.P., Woo, V., Soler, N.G., Pahor, A., Sugg, J., Rohwedder, K., Parikh, S., Long-term efficacy of dapagliflozin in patients with type 2 diabetes mellitus receiving high doses of insulin: A randomized trial. Ann Intern Med 156 (2012), 405–415.
    • (2012) Ann Intern Med , vol.156 , pp. 405-415
    • Wilding, J.P.1    Woo, V.2    Soler, N.G.3    Pahor, A.4    Sugg, J.5    Rohwedder, K.6    Parikh, S.7
  • 252
    • 84920263464 scopus 로고    scopus 로고
    • The impact of high-fat diet on metabolism and immune defense in small intestine mucosa
    • Wisniewski, J.R., Friedrich, A., Keller, T., Mann, M., Koepsell, H., The impact of high-fat diet on metabolism and immune defense in small intestine mucosa. J Proteome Res 14 (2015), 353–365.
    • (2015) J Proteome Res , vol.14 , pp. 353-365
    • Wisniewski, J.R.1    Friedrich, A.2    Keller, T.3    Mann, M.4    Koepsell, H.5
  • 253
    • 84875153197 scopus 로고    scopus 로고
    • Glucose transport families SLC5 and SLC 50
    • Wright, E.M., Glucose transport families SLC5 and SLC 50. Mol Asp Med 34 (2013), 183–196.
    • (2013) Mol Asp Med , vol.34 , pp. 183-196
    • Wright, E.M.1
  • 255
    • 78651349221 scopus 로고    scopus 로고
    • Biology of human sodium glucose transporters
    • Wright, E.M., Loo, D.D.F., Hirayama, B.A., Biology of human sodium glucose transporters. Physiol Rev 91 (2011), 733–794.
    • (2011) Physiol Rev , vol.91 , pp. 733-794
    • Wright, E.M.1    Loo, D.D.F.2    Hirayama, B.A.3
  • 256
    • 84869487801 scopus 로고    scopus 로고
    • Post-ischemic hyperglycemia exacerbates the development of cerebral ischemic neuronal damage through the cerebral sodium-glucose transporter
    • Yamazaki, Y., Harada, S., Tokuyama, S., Post-ischemic hyperglycemia exacerbates the development of cerebral ischemic neuronal damage through the cerebral sodium-glucose transporter. Brain Res 1489 (2012), 113–120.
    • (2012) Brain Res , vol.1489 , pp. 113-120
    • Yamazaki, Y.1    Harada, S.2    Tokuyama, S.3
  • 257
    • 84975229499 scopus 로고    scopus 로고
    • Sodium transport through the cerebral sodium-glucose transporter exacerbates neuron damage during cerebral ischaemia
    • Yamazaki, Y., Harada, S., Wada, T., Yoshida, S., Tokuyama, S., Sodium transport through the cerebral sodium-glucose transporter exacerbates neuron damage during cerebral ischaemia. J Pharm Pharmacol 68 (2016), 922–931, 10.1111/jphp.12571.
    • (2016) J Pharm Pharmacol , vol.68 , pp. 922-931
    • Yamazaki, Y.1    Harada, S.2    Wada, T.3    Yoshida, S.4    Tokuyama, S.5
  • 258
    • 84944718007 scopus 로고    scopus 로고
    • Activation of cerebral sodium-glucose transporter type 1 function mediated by post-ischemic hyperglycemia exacerbates the development of cerebral ischemia
    • Yamazaki, Y., Ogihara, S., Harada, S., Tokuyama, S., Activation of cerebral sodium-glucose transporter type 1 function mediated by post-ischemic hyperglycemia exacerbates the development of cerebral ischemia. Neuroscience 310 (2015), 674–685.
    • (2015) Neuroscience , vol.310 , pp. 674-685
    • Yamazaki, Y.1    Ogihara, S.2    Harada, S.3    Tokuyama, S.4
  • 259
    • 84904525477 scopus 로고    scopus 로고
    • Efficacy and safety of canagliflozin in patients with type 2 diabetes and stage 3 nephropathy
    • Yamout, H., Perkovic, V., Davies, M., Woo, V., de Zeeuw, D., Mayer, C., et al. Efficacy and safety of canagliflozin in patients with type 2 diabetes and stage 3 nephropathy. Am J Nephrol 40 (2014), 64–74.
    • (2014) Am J Nephrol , vol.40 , pp. 64-74
    • Yamout, H.1    Perkovic, V.2    Davies, M.3    Woo, V.4    de Zeeuw, D.5    Mayer, C.6
  • 260
    • 0032829063 scopus 로고    scopus 로고
    • Hypothalamic glucose sensor: Similarities to and differences from pancreatic beta-cell mechanisms
    • Yang, X., Kow, L.-M., Funabashi, T., Mobbs, C.V., Hypothalamic glucose sensor: Similarities to and differences from pancreatic beta-cell mechanisms. Diabetes 48 (1999), 1763–1772.
    • (1999) Diabetes , vol.48 , pp. 1763-1772
    • Yang, X.1    Kow, L.-M.2    Funabashi, T.3    Mobbs, C.V.4
  • 261
    • 27744547067 scopus 로고    scopus 로고
    • SGLT-1-mediated glucose uptake protects intestinal epithelial cells against LPS-induced apoptosis and barrier defects: A novel cellular rescue mechanism?
    • Yu, L.C., Flynn, A.N., Turner, J.R., Buret, A.G., SGLT-1-mediated glucose uptake protects intestinal epithelial cells against LPS-induced apoptosis and barrier defects: A novel cellular rescue mechanism?. FASEB J 19 (2005), 1822–1835.
    • (2005) FASEB J , vol.19 , pp. 1822-1835
    • Yu, L.C.1    Flynn, A.N.2    Turner, J.R.3    Buret, A.G.4
  • 263
    • 33748618171 scopus 로고    scopus 로고
    • LPS/CD14 activation triggers SGLT-1-mediated glucose uptake and cell rescue in intestinal epithelial cells via early apoptotic signals upstream of caspase-3
    • Yu, L.C., Turner, J.R., Buret, A.G., LPS/CD14 activation triggers SGLT-1-mediated glucose uptake and cell rescue in intestinal epithelial cells via early apoptotic signals upstream of caspase-3. Exp Cell Res 312 (2006), 3276–3286.
    • (2006) Exp Cell Res , vol.312 , pp. 3276-3286
    • Yu, L.C.1    Turner, J.R.2    Buret, A.G.3
  • 264
    • 84969915634 scopus 로고    scopus 로고
    • Efficacy and safety of sodium-glucose cotransporter 2 inhibitors in type 2 diabetes mellitus: Systematic review and network meta-analysis
    • Zaccardi, F., Webb, D.R., Htike, Z.Z., Youssef, D., Khunti, K., Davies, M.J., Efficacy and safety of sodium-glucose cotransporter 2 inhibitors in type 2 diabetes mellitus: Systematic review and network meta-analysis. Diabetes Obes Metab 18 (2016), 783–794, 10.1111/dom.12670.
    • (2016) Diabetes Obes Metab , vol.18 , pp. 783-794
    • Zaccardi, F.1    Webb, D.R.2    Htike, Z.Z.3    Youssef, D.4    Khunti, K.5    Davies, M.J.6
  • 265
    • 84864146681 scopus 로고    scopus 로고
    • LX4211, a dual SGLT1/SGLT2 inhibitor, improved glycemic control in patients with type 2 diabetes in a randomized, placebo-controlled trial
    • Zambrowicz, B., Freiman, J., Brown, P.M., Frazier, K.S., Turnage, A., Bronner, J., et al. LX4211, a dual SGLT1/SGLT2 inhibitor, improved glycemic control in patients with type 2 diabetes in a randomized, placebo-controlled trial. Clin Pharmacol Ther 92 (2012), 158–169.
    • (2012) Clin Pharmacol Ther , vol.92 , pp. 158-169
    • Zambrowicz, B.1    Freiman, J.2    Brown, P.M.3    Frazier, K.S.4    Turnage, A.5    Bronner, J.6
  • 266
    • 84889670998 scopus 로고    scopus 로고
    • Role of KATP channels in glucose-regulated glucagon secretion and impaired counterregulation in type 2 diabetes
    • Zhang, Q., Ramracheya, R., Lahmann, C., Tarasov, A., Bengtsson, M., Braha, O., et al. Role of KATP channels in glucose-regulated glucagon secretion and impaired counterregulation in type 2 diabetes. Cell Metab 18 (2013), 871–882.
    • (2013) Cell Metab , vol.18 , pp. 871-882
    • Zhang, Q.1    Ramracheya, R.2    Lahmann, C.3    Tarasov, A.4    Bengtsson, M.5    Braha, O.6
  • 267
    • 84954104372 scopus 로고    scopus 로고
    • Sodium-glucose linked cotransporter-2 inhibition does not attenuate disease progression in the rat remnant kidney model of chronic kidney disease
    • Zhang, Y., Thai, K., Kepecs, D.M., Gilbert, R.E., Sodium-glucose linked cotransporter-2 inhibition does not attenuate disease progression in the rat remnant kidney model of chronic kidney disease. PLoS One, 11, 2016, e0144640.
    • (2016) PLoS One , vol.11
    • Zhang, Y.1    Thai, K.2    Kepecs, D.M.3    Gilbert, R.E.4
  • 268
    • 84963706055 scopus 로고    scopus 로고
    • Sodium intake regulates glucose homeostasis through the PPARdelta/adiponectin-mediated SGLT2 pathway
    • Zhao, Y., Gao, P., Sun, F., Li, Q., Chen, J., Yu, H., et al. Sodium intake regulates glucose homeostasis through the PPARdelta/adiponectin-mediated SGLT2 pathway. Cell Metab 23 (2016), 699–711.
    • (2016) Cell Metab , vol.23 , pp. 699-711
    • Zhao, Y.1    Gao, P.2    Sun, F.3    Li, Q.4    Chen, J.5    Yu, H.6
  • 270
    • 0032945577 scopus 로고    scopus 로고
    • Whole body glucose metabolism
    • Zierler, K., Whole body glucose metabolism. Am J Phys 276 (1999), E409–E426.
    • (1999) Am J Phys , vol.276 , pp. E409-E426
    • Zierler, K.1
  • 271
    • 84944800184 scopus 로고    scopus 로고
    • Empagliflozin, cardiovascular outcomes, and mortality in type 2 diabetes
    • Zinman, B., Wanner, C., Lachin, J.M., Fitchett, D., Bluhmki, E., Hantel, S., et al. Empagliflozin, cardiovascular outcomes, and mortality in type 2 diabetes. N Engl J Med 373 (2015), 2117–2128.
    • (2015) N Engl J Med , vol.373 , pp. 2117-2128
    • Zinman, B.1    Wanner, C.2    Lachin, J.M.3    Fitchett, D.4    Bluhmki, E.5    Hantel, S.6


* 이 정보는 Elsevier사의 SCOPUS DB에서 KISTI가 분석하여 추출한 것입니다.